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Aplastic Anaemia (AA) is a rare haematological disease characterised by extreme depletion 
in the number of haematopoietic stem cells. Autoimmune attack by T-lymphocytes is the 
main mechanism for the depletion of stem cells. Another disease mechanism causing AA is 
dysfunctional telomere addition which results in shortened stem cell life span due to 
premature apoptosis. Mutations in both TERC and TERT, the key components of telomerase, 
have been detected in some patients with AA and have been shown to be responsible for the 
reduction in telomere length and premature stem cell death. Patients that have this alternate 
mechanism for AA development do not respond to immunosuppressive therapy (IST), the 
main chemotherapy option for patients with AA, thus, it is imperative that these mutations are 
detected prior to the initiation of this expensive and potentially life-threatening treatment.  
 
AIM 
The aim of the study was to develop a rapid diagnostic assay to detect clinically relevant 
telomerase mutations in AA patients.  
 
METHODS 
We generated plasmid based controls of TERT (G202A, C412T, G694A, C704T, A846G, 
T1015C, and G1090A) and TERC (del53-87, del110-113, G178A and C180T) mutations 
using PCR-based site-directed mutagenesis, followed by cloning of the mutated PCR product 
into pGEM-T-Easy vector. These plasmid-based mutants were diluted with wild-type 
genomic DNA and then used as templates to develop a multiplex assay system to detect 
seven TERT mutations and four TERC mutations using allele-specific primers in a standard 
PCR assay. Primers were combined to try to develop a one-tube assay to detect all four 
TERC mutations simultaneously and another to detect all seven TERT mutations, with the 
co-amplification of a control amplicon in both reactions. Assay optimisation was performed 
to create a single PCR cycling platform to allow amplification of all mutations 
simultaneously, which included cycling parameters, primer concentrations and the addition of 
additives such as DMSO and glycerol.  
xix 
 
A number of assay parameters such as mutation detection sensitivity, reproducibility and 
accuracy were tested, as well as the determination of the assay cost and turnaround time to 
assess its relevance in a diagnostic environment.   
 
RESULTS 
We successfully assessed DNA samples for all eleven clinically relevant telomerase 
mutations in a single PCR cycling platform. Allele-specific forward primers for all four 
TERC mutations: TERC53, TERC110, TERC178 and TERC180 were combined with a 
control amplicon forward primer and a common reverse primer to allow for simultaneous 
assessment of all mutations and the co-amplification of a positive control amplicon. The 
combination of all the primers necessary for the detection of seven TERT mutations proved 
to be more challenging, showing non-specific amplification and other mutants not amplified 
when all primers were combined. We had to develop two separate reaction mixes to solve the 
problems. TERT master mix one (TTMM1) reaction mix contained the primers necessary for 
the allele-specific detection of TERT412, TERT704, TERT846, TERT1015 and TERT1090 
while TERT master mix two (TTMM2) reaction mix allowed for the detection of TERT202 
and TERT694, as well as a positive control amplicon.  The developed TERC/TERT assay had 
a clinically relevant sensitivity of 2% mutant allele detection and showed good 
reproducibility and accuracy when known and blind samples of wild-type and mutants were 
assessed. The cost of the assay was found to be 2 times cheaper than the conventional direct 
sequencing alternative and 2.5 times faster – with an expected turnaround time of 4 hours.    
 
CONCLUSIONS 
We have successfully generated an allele-specific multiplex assay for the detection of TERC 
and TERT mutations that are associated with an alternate disease mechanism and IST failure 
in AA patients. This assay is cost-effective bearing in mind the detection of eleven mutations 
simultaneously and provides accurate results in a short time frame, making it suitable for use 
in a clinical molecular diagnostic laboratory.  
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1 CHAPTER ONE: LITERATURE REVIEW 
 




Aplastic Anaemia (AA) is a life threatening haematological disease, which belongs to a group 
of disorders known as Bone Marrow Failure Syndromes (BMFS) (Young et al., 2000, 
Gordon-Smith et al., 2001).  BMFS are characterised by the failure to generate a normal 
haematopoietic component within the bone marrow microenvironment, which in turn leads to 
the inappropriate generation of peripheral blood cellular components (i.e: leukocytes). These 
syndromes, which include AA, leukaemia (acute and chronic) and myelodysplastic syndrome 
(MDS), originate from the defects affecting the haematopoietic stem cells, such as increased 
proliferation, increased apoptosis or failure to differentiate (Gordon-Smith et al., 2001, Dokal 
and Vulliamy et al., 2003). In the case of AA, there is a reduction in the number of stem cells, 
which results in a deficiency in the number of all three major components of the peripheral 
blood, namely red blood cells (erythrocytes), white blood cells (leukocytes), and platelets, 
which is also collectively called pancytopenia (Calado et al., 2009). Similarly to other bone 
marow diseases, acquired AA (discussed below in more detail) is potentially a clonal disease 
affecting a specific cell lineage at an early point in development (haemopoetic stem cell) 
(Calado et al 2009 and Cooper et al., 2008) 
 
1.1.2 Clinical presentation and causes of AA 
AA has a broad spectrum of phenotypical symptoms ranging from fatigue, dizziness, pale 
skin, chest pains, headaches, coldness in palm of hands and feet and shortness of breath (Ball 
et al., 1998, Gordon-Smith et al., 2001, Fogarty et al., 2003). Several of these symptoms are 
caused by reduced levels of the iron-rich protein haemoglobin, which is present in 
erythrocytes and transports oxygen in the human circulatory system (Ball et al., 1998, Du et 
al., 2009). A reduction in erythrocytes and the consequential reduction in haemoglobin in AA 
patients cause the heart to work extremely hard to pump blood and circulate the highly 
needed oxygen to tissues (Dokal et al., 2003). This may lead to the development of other 
conditions such as arrhythmias, which may in turn result in heart failure (Ball et al., 1998, 
Gordon-Smith et al., 2001, Fogarty et al., 2003, Du et al., 2009). Anaemic hypoxia may also 
develop due to the reduced oxygen levels (Young et al., 1997).  
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The reduced white blood cell count in AA patients leaves patients vulnerable to bacterial and 
viral infections, due to a reduced immune response capacity. Many AA patients often present 
with multiple opportunistic infections and are more severely affected by common ailments 
due to the reduced immune response (Ball et al., 1998, Gordon-Smith et al., 2001, Fogarty et 
al., 2003). The reduction in platelets impairs the ability to form clots to repair wounds, as 
platelets produce necessary chemicals such as platelet derived growth factor (PDGF) required 
for tissue repair (Kagan et al., 1976; Gordon-Smith et al., 2001). This will in turn lead to 
symptoms of uncontrolled bleeding in the case of cuts and severe bruising. The severity of 
the disease is determined by bone marrow cellularity and peripheral blood cell count. This 
dictates the classification of AA patients as moderate AA, severe AA (SAA) or very SAA 
(VSAA) (Marsh et al., 2009).  
 
In addition to the symptoms and problems listed above, patients with SAA and VSAA are 
also prone to clonal development, resulting in MDS, acute leukaemia or paroxysmal 
nocturnal hemoglobinuria (PNH) (Shu-ye et al., 2012; Sutton et al., 2012). The risk of death 
is very high for SAA and VSAA cases (>12 months survival), with increased age being a 
negative prognostic factor (Marsh et al., 2009, Young et al., 2010). It is essential to treat AA 
as the disease is inevitably fatal. Most cases of AA are treatable, with overall survival 5-year 
rate being as high as 70% (Young et al., 2000, Gordon-Smith et al., 2001; Spellman et al., 
2012; Scheinberg et al., 2012). Fundamentally, AA is thought to be an autoimmune disease 
but the factors that trigger the development of the disease remains unclear. Unfortunately, the 
majority of AA cases are idiopathic, meaning that no known cause has yet been identified, 
which obviously makes prevention of this disease difficult. In the acquired category of this 
disease, there is evidence that exposure to different chemicals and drugs, including those used 
in chemotherapy regimens (i.e: benzene, chloramphenicol, carbamazepine, and others), 
though the incidences are minimal (Nguyen et al., 1999) can cause the disease. Furthermore, 
a virus called Parvovirus B19 (Erythrovirus B19) has been reported to be linked to acquired 
AA. This virus attacks the haematopoietic stem cells using P antigen as a receptor to invade 
cells and prevents the proliferation of a broad range of haematopoietic cells (Nguyen et al., 
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As part of an alternate disease mechanism (discussed below in detail), mutations in the 
telomerase complex have also been associated with both inherited and acquired forms of AA. 
In most cases of AA, the trigger for disease development is unresolved (Fogarty et al., 2003, 
Calado et al., 2009, Du et al, 2009).   
 
1.1.3 Immune attack as the main pathogenic mechanism in AA  
AA is characterised by extreme depletion in the number of haematopoietic stem cells. 
Patients with AA have an increased level of apoptosis of stem cells, which in turn results in 
the limited synthesis of all three cellular haematopoietic components as mentioned above 
(Young et al., 2006). In many patients, the main cause of stem cell reduction is due to an 
autoimmune response, where T-lymphocytes attack stem cells that are situated in the bone 
marrow (Carroll et al., 2009, Young et al., 2006). This autoimmune mechanism is mediated 
by the cytokines interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), which 
play a pivotal role in the pathogenesis of AA and are produced by the T-lymphocytes. They 
work synergistically in the suppression of haematopoiesis by activating the P38 Map Kinase 
pathway in the stem cells, which in conjunction with other activated downstream pathways 
consequently signals the apoptosis of these haematopoietic cells (Young et al, 1997, Verma 
et al, 2002, Sun et al., 2003).  
 
However, it is still not clear which mechanism and pathway is used by the T-lymphocytes 
and how they are initially triggered (Verma et al., 2002, Sun et al., 2003). Experiments 
conducted on cultured bone marrow cells from AA patients demonstrated that this may be 
due to an over expression of these cytokines (Verma et al., 2003) and an elevated level of 
activated cytotoxic lymphocytes (Kagan et al., 1976, Sato et al., 1995; Young et al., 1997). 
The activated T-lymphocytes attack the stem cells in the bone marrow, resulting in a 
hypocellular bone marrow (space, mostly replaced by fats) (Kagan et al., 1976; Verma et al., 
2003), and as a result the production of all haematopoietic progenitors is severely depleted 
(Passweg et al., 2010; Kim et al., 2011). Although T-lymphocytes have been shown to attack 
the stems cells in AA patients (Verma et al., 2003), it is not clear what causes this response 
and if in fact it is due to an underlying stem cell defect (Cooper et al., 2008, Passweg et al., 
2010, Kim et al., 2011). The success of stem cell transplants in AA patients suggests that the 
stem cells themselves give rise to the defective T-lymphocytes which deplete the stem cell 
pools from bone marrow, although the genetic defect in this pathogenic mechanism is not yet 
known (Young et al., 2010, Passweg et al., 2010, Kim et al., 2011, Scheinberg et al., 2012).  
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1.2 TREATMENT FOR AA  
 
1.2.1 Transplantation as a therapy in AA   
The most effective therapy in the treatment of BMFS, including AA, is stem cell 
transplantation (Young et al., 2006; Buchbinder et al., 2013). Unfortunately this procedure is 
not only costly and potentially life-threatening, it is also complicated by the need to find a 
suitable human leukocyte antigen (HLA) matched donor (Spellman et al., 2012). The 
complications of finding a suitable donor are even more difficult in a South African 
environment, where there are issues surrounding tissue/organ donation in some cultures and 
the mixed race ancestry of many South Africans. Transplantation does offer a cure and in the 
cases of SAA and VSAA it is viewed as the best therapeutic option (Arcese et al., 2006, 
Viollier et al., 2008, Chu et al., 2011, Buchbinder et al., 2013). It is also recommended in 
children and young adults with AA, but not in the elderly, who tend to recover less efficiently 
after the transplant although this is presently changing with new developments in research 
and new therapeutic regimens (Maury et al., 2009, Rocha et al., 2004, Passweg et al., 2010, 
Samarasinghe et al., 2012, Spellman et al., 2012).  
 
Transplanted cells replenish the bone marrow with healthy stem cells from a suitable donor, 
which is usually a family member (sibling or parent); HLA-matched unrelated donors (MUD) 
are also used in some cases (Deeg et al., 2006, Viollier et al., 2008, Spellman et al., 2012). 
Transplantation involves infusing the stem cells from a donor to the patient, which could 
have been harvested from the bone marrow, peripheral blood (after mobilisation of the stem 
cells from the bone marrow) or cord blood. The suitability of a donor is determined by a 
variety of parameters stipulated by The National Marrow Donor Program (NMDP) 
responsible for the search and identification of a suitable HLA matched donor. HLA are the 
group of proteins (i.e.: HLA-A, -B, -C, and -DRB1 loci) which play a pivotal role in the 
body’s self-defence from different foreign agents such as bacteria and viruses.  
 
In order for a donor to be suitable it requires that the HLA of a donor is closely related to the 
patient’s; otherwise the immune cells of the patient will recognize the donor’s cells as foreign 
and attack them or vice versa (Viollier et al., 2008, Spellman et al., 2012). Graft versus host 
disease (GVHD) is the attack of host cells by the donor/graft cells caused by immune 
incompatibility and can lead to severe complications for the patient (Deeg et al., 1998, 
Arcese et al., 2006, Chu et al., 2011, Kim et al., 2011, Scheinberg et al., 2012).  
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Graft rejection however, results from the attack of donor cells by the host’s immune response 
and is the major cause of graft failure (Maury et al., 2007). To prevent graft rejection, prior to 
the transplantation procedure, the patient is conditioned to prevent a stem cell attack by the 
host’s immunity (Flomenberg et al., 2004, Deeg et al., 2006). The conditioning is achieved 
through different approaches, but in most cases immunosuppressants are used, a prophylaxis 
therapy to deplete the host’s T-lymphocytes which may attack the transplanted stem cells 
after recognising them as foreign cells (Marsh et al., 2010, Novitzky et al., 2013).  
 
Transplantation is successful in many cases, but there are risks attached. These include the 
risk of infections post-transplant, due to the patients reduced immunity and the risk of 
developing either graft rejection or GVHD as mentioned above (Flomenberg et al., 2004, 
Deeg et al., 2006, Young et al., 2006, Spellman et al., 2012, Novitzky et al., 2013). All of 
these complications can be life-threatening. Due to the toxic chemotherapy agents used in the 
transplantation process and the strain on the haematopoietic cells, clonal mutation evolution 
can occur. The development of other BMFS such as MDS and leukaemia has been associated 
with a subset of transplanted patients (Young et al., 2006).  
 
Developments are currently underway to improve the outcomes of transplantation, including 
an improvement in conditioning procedures of patients prior to transplantation with an 
introduction of other strategies which are less aggressive and consisting of reduced intensity 
conditioning characteristics compared to other conditioning regimens (Maury et al., 2009, 
Marsh et al., 2010, Novitzky et al., 2013). Studies have indicated that using less aggressive 
regimens, such as a combination of fludarabine and cyclophosphamide and inclusion of 
alemtuzumab normally known as CAMPATH, improves long term survival of patients with 
fewer infections compared to the traditional intensive conditioning chemotherapy, which 
includes a combination of busulfan and cyclophosphamide and antithymocyte (ATG) (Maury 
et al., 2009, Marsh et al., 2010, Spellman et al., 2012, Novitzky et al., 2013).  
 
CAMPATH is also used as part of conditioning during the preparation of donated grafts for 
transplantation into recipient patients. This allows for the depletion of donor T-lymphocytes 
from the graft, reducing the likelihood of GVHD (Novitzky et al., 2009, Marsh et al., 2010). 
The reduced intensity conditioning regimens have been shown to be associated with an 
increased rate of engraftment and reduced GVHD, without the intensive immunodepletion to 
the recipient patient (Novitzky et al., 2009, Marsh et al., 2010, Novitzky et al., 2013). 
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1.2.2 Immunosuppression therapy in AA 
Transplantation is not an option for every AA patient due to the reasons explained above. 
Thus alternative treatment options are sought, even if these control the disease rather than 
cure it. Since the primary pathogenesis of AA has been well described, with the autoimmune 
attack by T-lymphocytes on haematopoietic stem cells being the defining feature of the 
disease, immunosuppressive therapy (IST) is usually the main chemotherapy for all AA 
patients (Young et al., 2006, Socie et al., 2007, Young et al., 2010, Spellman et al., 2012).  
The IST is usually a combination of cyclosporine (CsA) and ATG, which is used to control, 
but not cure the disease.   
 
ATG is used to treat several autoimmune disorders (Young et al. 2010, Affable et al, 2011). 
In AA patients, ATG exerts a range of effects on human immunology, which includes 
reducing the number of T-lymphocytes in the blood and peripheral tissues. It achieves this by 
modulating adhesion molecules and chemokine receptors on the surface of the T-
lymphocytes, thus blocking their function (Affable et al, 2011). It further increases the uptake 
of T-lymphocytes by the reticuloendothelial system (Tchervenkov et al., 2004). This down-
regulation of the immune system results in reduced apoptosis of hematopoietic stem cells, 
hence, better generation of stem cells in AA. CsA is also widely used in several immune-
mediated diseases; it acts by preventing the signal transduction needed to activate 
lymphocytes, thereby inhibiting an autoimmune attack (Stepkowsk et al., 1997). CsA is a 
cyclic 11 amino acid peptide normally produced pharmaceutically and biotechnologically 
using fungus Tolypocladium inflatum (Ranger et al., 2000, Jin et al., 2002, Wang et al., 
2005). It has a high affinity for cyclophilin A (CypA) and forms a complex molecule, CsA-
CypA, which binds to calcineurin (CnA), a calcium-calmodulin-activated serine/threonine 
specific protein phosphatase (Ranger et al., 2000, Huai et al., 2002, Jin et al., 2002). 
 
After binding, the complex becomes rigid and the regulatory and catalytic domains of CnA 
are inhibited, preventing the phosphatase function of the enzyme. The normal activity of CnA 
is to dephosphorylate the nuclear factor of activated T-lymphocytes (NFAT), which then 
activates T-lymphocytes. The CsA molecule therefore inhibits this activation process (Ranger 
et al., 2000, Jin et al., 2002, Wang et al., 2005).  
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The combination of ATG and CsA allows a synergistic approach to reduce the attack of 
haematopoietic progenitors by activated T-lymphocytes. However, despite the successful 
utilization of IST in some patients, only 60% of AA patients respond to therapy (Yamaguchi 
et al., 2005, Vulliamy et al., 2005, Young et al., 2006, Calado et al., 2008, Young et al. 
2010). This suggested that alternative and as yet undescribed disease mechanisms exist in AA 
and research in the past few years has embarked on trying to unravel the disease 
mechanism(s) of these unresponsive AA patients. One such mechanism involves proteins that 
form part of the telomerase complex and is the basis for the research undertaken in this thesis. 
 
 
1.3  TELOMERASE COMPLEX AND DISEASE PATHOGENESIS  
 
1.3.1 Telomerase complex and AA disease pathogenesis 
1.3.1.A: Alternate disease mechanism for AA  
Apart from an autoimmune attack by T-lymphocytes, a second disease mechanism for AA 
development involves inefficient telomerase complex in the haematopoietic stem cells. The 
telomerase complex includes a reverse transcriptase (TERT), an RNA template (TERC) and 
associated proteins (dyskerin, NOP10, NHP2 and GAR) and is responsible for genomic 
stability by capping the chromosome with telomeres (Yamaguchi et al., 2005, Vulliamy et 
al., 2005, Young et al., 2006). Reduced functioning of this complex results in incomplete 
chromosome capping, activation of DNA repair mechanisms and then signalling of cellular 
apoptosis (Verma et al, 2002, Young et al., 2006). In AA, reduced telomerase complex 
activity results in a reduced stem cell pool due to premature cell death (Yamaguchi et al., 
2005, Du et al., 2009) 
 
This mechanism was initially shown to occur in a number of AA patients who did not 
respond to IST therapy (Kagan et al., 1976, Verma et al, 2002). Patients were found to have 
haematopoietic stem cells and leucocytes that demonstrated shortened telomeres in 
comparison to cells from age-matched controls (Ball et al., 1998, Oshima et al., 2003). 
Further investigation revealed that these patients had reduced telomerase activity (Greenwood 
et al., 2003, Yamaguchi et al., 2005, Marrone et al., 2007) and telomerase complex mutations 
(Vulliamy et al., 2007, Calado et al., 2008, DU et al., 2009).  
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Studies using plasmid constructs of either WT or mutated TERC or TERT genes showed that 
cultures transfected with mutated genes showed reduced telomerase activity (Yamaguchi et 
al., 2005, Marrone et al., 2007). Researchers also showed that cell death was more prominent 
in cultures of haematopoietic cells from some AA patients (Young et al, 1997, Verma et al, 
2002). This indicated that mutations harboured within TERT and TERC genes were part of 
AA disease pathogenesis, especially in patients who did not respond to IST. 
 
1.3.1.B: Telomerase complex and telomere formation    
1.3.1.B.i: Telomeres  
Telomeres are tandem repeat DNA sequences (i.e. repeats of TTAGGGn) situated at the end 
of eukaryotic chromosomes (Figure 1.1) and also on some prokaryotic chromosomes (Cong 
et al., 2002, Mitchell et al., 2010). Eukaryotic organisms normally have a long linear 
chromosomal DNA which is prone to DNA loss during each cell replication cycle. To 
prevent the loss of important coding sequences, the chromosomes are completed by the 
addition of protective telomeres (Young et al., 2006; Calado et al., 2012). This process is 
important in cells capable of cell division, and is therefore normally limited to stem cells, 

































Figure 1. 1: Telomeres at the end of chromosomes 
Telomeres (yellow) were microscopically visualized at the ends of chromosomes (four yellow signals of 
telomeres either side of chromosome) via fluorescence in situ hybridization (FISH).Telomeres are capping the 
chromosomal ends to protect the loss of genomic information after each replication during cell division (Young 
et al., 2010).   
 
 
1.3.1.B.ii: Telomerase complex  
The formation of telomeres requires a coordinated effort from a collection of proteins that 
form part of the telomerase complex (Figure 1.2). These include TERT and TERC (forming 
telomerase), the ribonucleoprotein subunit 1 (GAR1; 25 kDa), the ribonucleoprotein subunit 
2 (NHP2; 22 kDa), the ribonucleoprotein subunit 3 (NOP10; 10kDa) and the 
ribonucleoprotein subunit 4 (dyskerin or DKC1; 57 kDa) (Calado et al., 2008; Mitchell, et 
al., 2010). While TERT and TERC are the main components, the accessory proteins play a 
key role in processing TERC molecules and stabilising the complex. DKC1 binds to TERC 
for stabilization within the complex, GAR1 modifies small nuclear RNA for the pre-
processing of TERC, while NHP2 is required for biogenesis of ribosomes for protein 
assembly within the complex and NOP10 provides the correct intramolecular processing and 
trafficking (moving within the cell) of TERC within the telomerase complex. The proper 
coordination of these different components within the telomerase complex ensures that the 
telomeres are synthesised correctly for capping of the chromosomes (Ly et al., 2005; Calado 
et al., 2008).  
 




Figure 1.2: Schematic diagram of the telomerase complex. 
The picture above shows the synthesis of telomeres via the telomerase complex indicating the TERT and TERC 
including associated proteins (dyskerin, NOP10, NHP2 and GAR1) that play a pivotal role for RNA stability in 
the complex. Telomeres are capping the end points of chromosomes after DNA replication. The picture was 
adapted from Calado and Young (2008) and modified.  
 
 
TERC RNA molecule contains various core domains: CR2/CR3 (together called core-
pseudoknot), CR4-CR5, box H/ACA (CR6/CR8), and CR7, as well as the hypervariable 
paired region, which can have flexible length and sequence (Figure 1.3) (Chen et al., 2002). 
Each of these domains plays a significant role during the interaction of TERC and TERT to 
ensure that the RNA substrate is processed appropriately for the synthesis of telomeres, thus 
the telomerase activity is dependent upon specific domains of TERC for normal functioning 
(Ly et al., 2005; Chen et al., 2008). The 5’region (core-pseudoknot domain) contains the 
telomere-encoding domain and forms a specific secondary structure to expose this template 
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It also plays a vital role during telomerase assembly by facilitating dimerization of TERC (Ly 
et al., 2005; Mitchell, et al., 2010). The box H/ACA domain and CR7 ( 3’region) allow direct 
binding of DKC1 and other accessory proteins to ensure accurate processing of TERC and 
correct exposure of the TERC encoding core-pseudoknot domain (5’region) (Ly et al., 2005; 
Mitchell, et al., 2010). They also play an important role in the localisation of TERC within 
the nuclear compartment of the cell via the nucleolar-targeting signal (NTS) mechanism 




Figure 1. 3: Schematic diagram showing the structure of TERC 
The image showing TERC with its core domains: CR2/CR3 (Core Pseudoknot) the 5’ encoding region, CR4-
CR5, box H/ACA, and CR7 domains (both located at the 3’region), and the hypervariable paired region. The 
picture was adapted from Ly et al., (2005) and modified to indicate certain regions.  
 
 
TERT consists of C-terminal region, reverse transcription region and N-region (Figure 1.4), 
which are crucial for the proper interaction with the TERC template. The C-terminal region 
comprises of highly conserved domains (E-I, E-II, E-III, and E-IV) that provide direct 
intramolecular interaction between TERC and TERT during the complex formation and are 
vital for enzymatic function (Pogacic et al., 2000; Chen et al., 2002; Ly et al., 2005, Calado 
et al, 2008). The reverse transcription region is the catalytic region of the protein and 
contains seven domains (1, 2, A, B, C, D and E), all of which are important for transcription 
of TERC. 
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The N-terminal region comprises of the N-terminal domain (TEN), the CP domain, and the 
QFP domain, which play a crucial role for RNA (TERC) interaction (Calado et al, 2008). It 
also comprises of an anchor site that binds primer nucleotides for the determination of 
nucleotides repeats that would be processed and added during telomeres synthesis (Pogacic et 




Figure 1. 4: Schematic diagram showing the structure of TERT 
Schematic diagram of TERT showing the various regions and domains in the protein, N-terminal with its 
domains (TEN, CP, QFP and T), reverse transcription region comprises of domains 1, 2, A, B, C, D and E, and 
C-terminal region containing domains E-I, E-II, E-III, and E-IV (Calado et al., 2008).   
 
 
In summary, telomere synthesis is achieved through properly coordinated interactions within 
the telomerase complex, where the 5’ region of TERC and the reverse transcription region of 
TERT are responsible for the direct formation of the telomeres (Lin et al., 2008; Calado et al., 
2008; Mitchell et al., 2010). The 3’region of TERC interacts with accessory proteins to 
provide stability and proper processing of RNA (TERC) within the complex (Pogacic et al., 
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1.3.1.B.iii: Shelterin and telomerase complex interactions  
In addition to the telomerase complex, the shelterin complex is involved in the synthesis of 
telomeres. The shelterin complex comprises of the telomeric repeat binding factor 1 (TRF1), 
TRF2, the TRF1-interacting protein 2 (TIN2), protection of telomeres 1 (POT1), the POT1-
TIN2 organizing protein (TPP1, also known as TINT1, PTOP or PIP1) and the repressor or 
activator protein 1 (RAP1) (Ye et al., 2004, de Lange et al., 2005, Chen et al., 2008).   
 
As telomeres are synthesised to cap chromosome, they form a structural loop called the 
“telomeres loop”, normally known as the T-loop (Figure 1.5). The T-loop is generated 
through the coiling of the 3’ end of the telomeric overhang onto the double stranded 
telomeres and this is facilitated by proteins of the shelterin complex (Griffith et al., 1999; de 
Lange et al., 2005, Calado et al., 2012). Towards the end of the T-loop, a single-stranded 
telomere DNA that has a complementary sequence to either strand of DNA at the 
chromosomal end is formed (de Lange et al., 2005). It binds to one of two strands and forms 
a triple-stranded DNA displacement loop (D-loop)that prevents base pairing to one of the two 
strands, thus, maintaining the appropriate chromosomes (Ye et al., 2004; de Lange et al., 
2005). Failure in the shelterin complex results in the inability to protect chromosomes 
properly, leading to DNA repair system to be triggered to repair chromosomal ends (Griffith 











Figure 1.5: A diagram illustrating the shelterin complex during chromosome capping 
The picture above shows the shelterin complex interacting with telomeres during the capping of chromosomes 
after DNA replication. Proteins of shelterin that are involved in the formation of T-loop and D-loop, responsible 
for chromosomal ends protection are shown binding to the telomeres and collectively provide a shielding 
mechanism for the chromosomal ends (Calado et al., 2012) 
 
 
1.3.1.B.iv: Consequences of incomplete telomere capping 
The proper capping of the ends of chromosomes ensures that the 3` end of telomeric DNA is 
not recognised by the cell’s DNA damage machinery as a double strand break (DBS) and that 
the DNA damage response (DDR) is not triggered. However, if the synthesis of telomeres is 
impaired and the capping of chromosomes is incomplete, a potent DDR is elicited (Deng et 
al., 2008). This leads to the expression of DDR markers such as phosphorylated γ-H2AX, 
53BP1, NBS1, MDC1 and CHK2, amongst others. These proteins localize to the telomeres 
forming dysfunctional telomere-induced foci (TIFs), which have been described as a feature 
of senescent cells. Alternatively, dysfunctional telomeres have also been shown to activate 
cell cycle checkpoints such as the PI3 kinase ATM (ataxia-telangiectasia mutated) and ATR 
(ataxia-telangiectasia and Rad3 related). These kinases phosphorylate downstream CHKI and 
CHK2 kinases, which in turn phosphorylate p53. The phosphorylation of p53 results in the 
displacement of its sequester, murine double minute 2 protein (MDM2), thus, preventing its 
targeting for ubiquitin-dependent degradation.  Therefore, the stabilized p53 proceeds to 
stimulate the expression of the cyclin-dependent kinase inhibitor p21, promoting cell cycle 
arrest or apoptosis (Young et al., 2005, Calado et al., 2012).   
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1.3.1.C: Telomerase complex mutations associated with AA pathogenesis 
As mentioned earlier, studies have shown that AA patients have shortened telomere lengths 
on their chromosomes (Yamaguchi et al., 2005; Vulliamy et al., 2007; Calado et al., 2008; 
Calado et al., 2012). This led researchers to investigate the corresponding telomerase activity 
and take a closer look at the genetics of both the TERT and TERC components to try to 
identify possible disease causing mutations (Yamaguchi et al., 2005; Young et al., 2006; 
Calado et al., 2008; DU et al., 2009). This was stimulated by the finding that dyskeratosis 
congenita was actually caused by the inheritance of telomerase mutations (Vulliamy et al., 
2002). Comparative studies have shown that haematopoietic stem cells and leucocytes from 
AA patients harbour mutations and have altered telomere length compared to cells from age-
matched healthy individuals. Table 1.1 shows a list of mutations that are associated with AA. 
Although many mutations have been discovered, these particular ones listed were found to be 
associated with reduced telomerase enzyme activity in cells harvested from patients 
harbouring these mutations. In most studies, the frequency of mutations in either of these 
genes was found to be about 5-10% (Yamaguchi et al., 2005; Young et al., 2006;  Vulliamy 
et al., 2007; Calado et al., 2008; Du et al., 2008). 
 
 
All these mutations have been found in AA patients that have failed to respond to IST therapy 
or have only a transient response. It is therefore postulated that the presence of these 
mutations serves as a diagnostic feature of this alternate disease mechanism and detecting 
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Table 1.1: TERT and TERC mutations associated with AA 
 
*: Mutations of TERT and TERC associated with AA, depicted according to their exons, the base changes in the 
DNA sequence and the amino acids before base change and after mutation, mutants names are shown in 
brackets for  conveniently used throughout the manuscript.  
#
: Profile of telomerase activity - as measured by telomeric repeat amplification analysis of cell lysates and 
average telomere length at chromosomal ends by flow fluorescence in situ hybridization from AA patients 
peripheral blood cells compared to aged match healthy individuals (Yamaguchi et al., 2005; Du et al., 2009; 
Calado et al., 2008).  
$
:  Response to IST response as measured by blood cell count and increased in cell count showing response 
(Yamaguchi et al., 2005; Young et al., 2006; Vulliamy et al., 2007; Du et al., 2009). 
Ω
: References for the studies investigated mutations, telomerase activity and patient’ response from IST.  
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The interaction between TERC and TERT is essential for telomerase activity and telomere 
formation and is dependent upon the structure of both. Mutations within these two telomerase 
complex components affect the normal functioning of the system leading to inappropriate 
interactions between TERC and TERT and associated proteins, resulting in reduced activity of 
the telomerase and ineffective telomere formation (Yamaguchi et al., 2005, Young et al., 
2006, Du et al., 2008, Calado et al., 2008, Du et al., 2009). Some mutations result in no 
telomerase activity at all while others reduced the enzyme activity significantly (Young et al., 
2006, Du et al., 2008, Calado et al., 2008).  
 
The mutations affect telomerase activity in different ways depending on the location of these 
mutations within the various structures and the role that these structures play in the 
interactions between different components. Mutations of TERT gene (listed in Table 1.1) 
result in reduced enzyme activity and are found in different domains of the enzyme. 
TERT202 and TERT412 are found in the N-terminal region, a domain crucial for substrate 
(TERC) interaction. TERT694, TERT704 and TERT846 occur in the reverse transcription 
region, the catalytic region, while TERT1015 and TERT1090 are found in the C-terminal 
region which is very important for the intramolecular interactions of TERC and TERT as the 
complex assembles (Pogacic et al., 2000, Chen et al., 2002, Ly et al., 2005, Calado et al, 
2008).   
 
Mutations of TERC which are directly associated with IST failure are also linked with 
reduced telomerase activity, as opposed to total inhibition. All four TERC mutations: 
TERC53, TERC110, TERC178 and TERC180 occur in the 5’ core-pseudoknot domain on a 
template region shown in Figure 1.6 (Pogacic et al., 2000, Vulliamy et al, 2007). This leads 
to decreased substrate to enzyme interaction, resulting in low enzyme activity, and also 
incorrect coding of telomeres that cause an incorrect sequence product and also cause less 
interaction to the enzyme for proper telomeres sequence synthesis (Pogacic et al., 2000, 
Calado et al., 2008; Du et al., 2009).  
 




Figure 1. 6: Schematic diagram TERC showing the location of mutations  
Schematic structure of TERC depicting the positions of mutations spanning across the structure of TERC and 
showing the base changes and deletions. The picture was adapted from Ly et al., (2005) and modified to indicate 
certain regions and mutations. 
 
 
As mentioned earlier, IST is the main chemotherapy for AA patients. However if a patient 
harbours the specific mutations shown in Table 1.1 they are very likely to have the alternate 
disease mechanism for AA pathogenesis and therefore would not respond to this type of 
therapy. If given IST therapy their condition could deteriorate and the patient be exposed to 
unnecessary secondary infections due to the therapy and even die because of the on-going 
disease (Young et al., 2006, Calado et al., 2008). Therefore, for survival of these patients, an 
urgent transplant would be necessary (Gordon-Smith et al., 2001, Young et al., 2006, Calado 
et al., 2009). Some of these mutations have an inheritable link (Young et al., 2006; Calado et 
al., 2008); therefore, it is essential to screen the family members for mutations prior to 
transplantation to screen out these donors (Yamaguchi et al., 2005, Du et al., 2009). Thus, 
detecting and knowing the TERC/TERT mutation status prior to initiating any therapeutic 
strategy for AA patients is a crucial step for the decision making about therapy.  In most 
cases 5%-10% of AA patients have both TERC or TERT mutations and likely 15-20% of 
those mutations are investigated in this work.  
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1.3.2 Mutations of telomerase complex associated with other diseases  
1.3.2.A: Idiopathic Pulmonary fibrosis and liver cirrhosis  
Studies investigating the involvement of telomere length in the pathogenesis of idiopathic 
pulmonary fibrosis (IPF) and liver cirrhosis have found that telomerase complex dysfunction 
contributes towards these two diseases (Rudolph et al., 2000, Tsakiri et al., 2007, 
Chaiteerakij et al., 2011, Calado et al., 2011, Hartmann et al., 2011). Studies investigating 
telomere length and telomerase activity in the hepatic stem cells (liver cells) and pulmonary 
stem cells (lung cells) extracted from either IPF or liver cirrhosis patients showed reduced 
telomerase activity and significantly shortened telomeres compared to cells from age matched 
healthy individuals (Tsakiri et al., 2007, Calado et al., 2011, Hartmann et al., 2011). 
Furthermore, studies conducted using mouse models deficient of TERC genes showed failure 
to regenerate liver cells after a partial hepatectomy compared to WT mice that had sufficient 
regeneration of the liver and exhibited reduced cirrhosis (Rudolph et al., 2000).  
 
Mutations linked to IPF have been shown in the TERC gene are A37G (Ly et al, 2005), 
G182A (Kirwan et al., 2011) and two AA associated deletions [TERC53 and TERC110 
(Table 1.1)]. Four TERT mutations [TERT202, TERT412, TERT694, TERT772, and 
TERT1090 (Table 1.1)] were found to be associated with AA pathogenesis. Other mutations 
associated with IPF and liver cirrhosis are G33524A (Arg>His), G45569A (Ala>Thr) 
(Yamaguchi et al., 2005), as well as C5155T (Pro>Ser) (Tsakiri et al., 2007), T5222A 
(Leu>Gln) (Armanios et al., 2005), G5592A (Val>Met), C6618T (Arg>Cys) (Tsakiri et al., 
2007),  C21268T (Ala>Val) (Du et al., 2009), G27852A (Val>Ile), and C33558G (His>Gln) 
(Du et al., 2008). Although detecting these mutations in IPF and liver cirrhosis patients does 
not have a direct effect on therapeutic decisions, screening their family members could be 
beneficial as a precautionary measure to prevent disease development. The failure of 
pulmonary cells and hepatic cells to regenerate due to mutations of TERC and TERT shows 
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1.3.2.B: Dyskeratosis congenita  
Dyskeratosis congenita (DKC) is another disease linked to the malfunctioning of the 
telomerase complex due to the mutations found within the genes of the various role-players. 
It is a rare inheritable disorder characterised by skin pigmentation problems, nail dystrophy 
and bone marrow failure (Vulliamy et al., 2006; Du et al., 2009).Mutations of TERC, TERT 
and DKC1 genes affects haematopoietic stem cells and activate leucocytes leading to 
premature stem cell ageing and death. Studies have shown that these mutations play a major 
role in DKC disease progression (Vulliamy et al., 2001, Vulliamy et al., 2006; Du et al., 
2009). Mutations in the TERC gene that are associated with AA have been found in DKC and 
these mutations are TERC53, TERC110, TERC178 and TERC180 (Table 1.1). Specific 
mutations associated directly with DKC are C408G and GC107AG (Vulliamy et al., 2001).  
 
Two mutations found in TERT gene (TERT412, TERT704) from patient suffering from AA 
were also found in DKC patients .Studies have delineated other TERT mutations that are only 
associated with DKC; A27796G (Tyr>Cys) (Yamaguchi et al., 2005), C28892T (Arg>Cys), 
C35502T (Arg>Trp) (Marrone et al., 2007) and G35507C (Lys>Asn) (Armanios et al., 
2005). Since DKC is part of the BMFS and in most cases transplantation is the main 
cure/treatment for DKC patients, screening the donor for these mutations is vital.  
 
1.3.3 Null mutations in the telomerase complex  
Apart from reported pathogenic telomerase complex mutations, there is evidence describing 
point mutations within TERC and TERT that are not associated with disease. These include 
several mutations that seem to be race-specific, including TERC mutations G58A (Vulliamy 
et al., 2002, Yamaguchi et al., 2003) and G228A (Yamaguchi et al, 2003, Marrone et al., 
2004). G58A has been shown to occur at a frequency of 4-10% and G228A occurs at a 
frequency of 82% in African Americans. G58A is located in the telomere coding region 
(core-pseudoknot domain), a highly conserved region, thus, impacts negatively on TERC and 
TERT interaction for proper synthesis of telomeres and it was assumed that it may reduce or 
stop telomerase activity. However, investigators found that this mutation had no significant 
effect on the telomerase activity giving similar activity as the WT in in vitro studies and is 
thus regarded as a null mutation (Fu et al., 2003, Ly et al., 2003, Marrone et al., 2004). 
Investigations on the G228A have shown that this mutation does not confer any susceptibility 
to diseases pathogenesis (Yamaguchi et al., 2003, Marrone et al., 2004).  
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These findings show that it is imperative to look for specific mutations when assessing the 
patient for mutations associated with specific disease. Sequencing either the whole TERC 
gene or relevant TERT exons may detect point mutations that are not related to disease.  
 
 
1.4 VARIUOS TECHNIQUES AND METHODS TO DETECT MUTATIONS  
 
There are many techniques that are used to detect mutations in human genomic DNA. These 
include allele-specific PCR, standard Sanger sequencing, next generation sequencing (NGS), 
and real-time PCR using hydrolysis or hybridisation probes. Below we discuss other possible 
techniques which can be used to detect mutations too.  
 
1.4.1 Sequencing for mutation detection 
While the sequence analysis of TERC would be very productive, allowing the detection of all 
4 mutations in the same PCR and sequencing reaction, the analysis of TERT is more 
involved, requiring at least 4 reactions. Both strands of the amplicon would also need to be 
sequenced, to limit sequencing artifacts and impurities thus analysis in duplicate would be 
preferential to be certain that the mutations were not introduced in error by Taq polymerase. 
Standard sequencing also has a detection sensitivity of 20- 30% (Kollner et al., 1993). While 
this is sensitive enough for inherited mutations, clonal mutation development would have to 
be fairly advanced to detect the mutations. As sequence analysis is a post-PCR technique, 
which requires purified amplicon for the reaction, extra time is also required for this analysis. 
This is compounded by the need to analyse all the sequencing data and compare it to WT 
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1.4.2 NGS for mutation detection 
NGS is a new sequencing technology that is used primarily to sequence large tracts of DNA 
(Izawa et al., 2013). During NGS, DNA is fragmented into small fragments which are then 
sequenced in different parallel reactions and the results are assembled for analysis (Dong et 
al., 2012; Sule et al., 2013). NGS is highly sensitive to detect point mutations thus giving an 
advantage over other techniques (Sule et al., 2013). Unfortunately, although NGS offers a 
sensitivity advantage over standard sequencing, the cost is currently quite prohibitive and the 
requirement of novel hardware for the analysis may limit its use in developing countries that 
do not have requisite skills and funds. 
 
1.4.3. Real-time PCR 
Real-time PCR is another powerful molecular technique which allows the PCR reaction to be 
monitored during cycling, through the activation of a fluorescent molecule, which can be 
attached to a sequence-specific probe or incorporated into the double-stranded product (i.e: 
syber green) (VanGuilder, et al., 2008). Through the use of hydrolysis or hybridisation 
probes, it is possible to detect amplification of a mutated product only. This approach is 
highly sensitive and very specific (Reynisson et al., 2006, VanGuilder, et al., 2008). 
However, each mutation requires a specific probe and current multiplex technology on this 
platform does not allow the simultaneous detection of more than 3 products simultaneously 
(Luo et al., 2011). Although real-time PCR has advantages in detection of these mutations 
(specificity and sensitivity), the drawback is the expensive reagents required, the inability to 
effectively multiplex all the mutations and the need for specialised molecular equipment, 
which is an issue particularly in developing countries that lack resources.  
 
1.4.5 Allele-specific multiplex PCR 
Allele-specific multiplex PCR is a rapid molecular technique which is applicable in many 
areas of DNA analysis. It allows a combination of reactions using different pairs of primers 
that are used in one tube to amplify two or more target sequences (Chamberlain et al., 1988, 
Newton et al., 1989, Edkins et al., 1996). Allele-specific primers are 100% homologous to 
the mutant sequence and have base differences located specifically at the terminal 3' end of a 
forward primer to allow for amplification to occur only in the presence of mutations. This 
technique ensures that the mutated sequences are preferentially amplified over the WT DNA 
sequence. Allele-specific primers are preferable because they bring this discriminatory factor 
compared to standard PCR primers.  
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Although allele-specific primers brings the advantage of detecting mutations by amplifying 
only in the presence of a mutation, sometimes the WT DNA is amplified since the difference 
between allele-specific primer and WT DNA sequence is only one base at 3’end of primer.  
Chemically modified primers can enhance the discrimination factor of allele-specific primers. 
These modifications can be achieved by using locked-Nucleic Acid (LNA) primers, Zip-
Nucleic Acid (ZNA) primers or peptide nucleotide acid (PNA) primers (Maertens et al., 
2006, Moreau et al., 2009, Terahara et al., 2011).  
 
Chemically modified primers based on either LNA or ZNA provides a thermal stability to the 
primers by increasing the annealing temperature which aids to increase specific amplification 
as the primers would not be able to bind to the WT DNA but would only bind to their targets 
(Moreau et al., 2009, Paris et al., 2010, Ivanova et al., 2011). PNA based primers also 
increase specificity by allowing the PNA to bind to the WT DNA sequence and leaving 
allele-specific primers to bind only to their targets (Terahara et al., 2011). Using PNA 
primers clamping system requires that two sets of oligonucleotides are designed for the PCR 
reaction, one is PNA and another is allele-specific primers and both sets are used in one 
reaction. Therefore chemically modified primer could be potentially used as an option to 
improve specificity of the allele-specific multiplex PCR if 3’end based primers bind to the 
WT DNA. However chemically modified primers may increase costing since it’s a new 
technology. 
 
Some of the phenomenal applications for the allele-specific PCR which have been well 
described are detection of gene deletions, analysis of polymorphisms and mutations and DNA 
quantitative analysis (Newton et al., 1989, Edkins et al., 1996, Markoulatos et al., 2002, 
Hindiyeh et al., 2005). Multiplex PCR as a concept solves many issues, but it also comes 
with its own challenges due to the introduction of multiple primer sets and different sized 
amplicons being produced. In a singleplex reaction, where there is only a single pair of 
primers, the primers can be designed to prevent non-specific binding and primer 
dimerization. However, in a multiplex environment, even well-designed primers start to 
behave differently and require a lot of optimization to ensure that the reaction is successful 
(Chamberlain et al., 1988, Markoulatos et al., 2002, Schoske et al., 2003). These difficulties 
include favouring of a certain target to be amplified against others, poor specificity and 
sensitivity (Markoulatos et al., 2002).  
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This occurs because a PCR reaction requires a certain primer to template ratio, and once 
another primer pair is introduced in the reaction, the ratio changes and the PCR reaction is 
compromised (Markoulatos et al., 2002, Schoske et al., 2003). In most cases in a multiplex 
PCR, non-specific PCR products are formed, primer dimers are also synthesized, and this 
impairs the efficiency of PCR reaction (Henegariu et al., 1997, Loffert et al., 1999). The non-
specific products consume reaction reagents, which in turn compromises the annealing and 
extension to the target regions. As indicated above, designing specific primers that would not 
cause primer-dimer formation is crucial for any PCR, but with a multiplex PCR it is 
challenging since multiple primers are used in one reaction. Thus finding a common 
annealing temperature is not easy as these primers are binding in different DNA sequences, 
some with high GC content which raises the Tm, while others with high AT content causing 
low Tm.  
 
Generally, all the primers in the multiplex PCR should have a similar predicted melting 
temperature (Tm) to avoid non-specific binding but the practicality is determined by a region 
where the target gene to be amplified is located (Chou et al., 1992, Wagner et al., 1994, 
Loffert et al., 1999, Markoulatos et al., 2002). Furthermore, the reagents interactions 
fluctuate in the multiplex PCR that causes an amplification of certain products of interest 
while others are not amplified. This favouring of certain amplification in a multiplex PCR is 
called PCR drift (Walsh et al., 1992). Optimization is required to improve amplification in 
the multiplex PCR. 
 
 During optimization of the multiplex PCR, it is important to perform singleplex PCR 
reactions, using each primer pair separately. Furthermore, it is important to optimize the 
concentration of PCR reagents (i.e. dNTP’s, primers and enzymes) since in a multiplex PCR 
different amplicons are usually amplified concurrently (Henegariu et al., 1997, Markoulatos 





is critical in the PCR reaction since Taq DNA polymerase 
is a magnesium-dependent enzyme (Markoulatos et al., 2002). Magnesium chloride binds 
also to the double stranded DNA, hence, if it is in excess it could stabilize the template and 
affect completion of denaturation, which could decreases the PCR product.   
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Furthermore, if magnesium chloride
 
concentration is in excess, it could increases the non-
specific primer binding which would increase non-specific products and decreases sensitivity. 
However, inadequate magnesium chloride
 
concentration may also decrease the amplicon 
production or lead to no amplification at all (Loffert et al., 1999, Markoulatos et al., 2002). 
Other than the optimisation of PCR reagents, the cycling conditions may also change during a 
multiplex scenario as compared to the single-plex reactions. Considering decrease/increase 
annealing temperature, increase extension time, could also be checked if it has an impact in 
the multiplex PCR to produce a target amplicon and minimizes the non-specific products, this 
helps to find suitable common cycling conditions (Loffert et al., 1999, Markoulatos et al., 
2002).   
 
The additives in the multiplex PCR have also been indicated to improve the efficiency of 
PCR, especially in a multiplex setting. Adding dimethyl sulfoxide (DMSO), glycerol, 
formamide and bovine serum albumin (BSA) in multiplex PCR reactions have been shown to 
improve the efficacy of the reaction (Masoud, et al., 1992, Henegariu et al., 1997, 
Markoulatos et al., 2002). DMSO is suggested to enhance the PCR efficiency by using 
various mechanisms such as DMSO decreasing the Tm of the primers, affecting the thermal 
activity profile of Taq DNA polymerase, and enhances the effective denaturation of the 
double stranded template (Masoud, et al., 1992, Walsh et al., 1992). Glycerol relaxes DNA, 
helping the primers to bind easily to their specific target sequences in a multiplex PCR setting 
(Markoulatos et al., 2002). While BSA is suggested to improve a multiplex PCR efficiency 
by affecting the reaction in different ways, but on how it works is not clearly described. 
 
As each unique primer pair is added to the multiplex reaction, the reaction becomes 
susceptible to primer dimerization. To improve the success of multiplex PCR, hot-start 
applications have been introduced to ensure that the key components of PCR remain inactive 
until high temperature of thermo cycling (Henegariu et al., 1997). This can either be achieved 
by keeping all reactions at a very low temperature before cycling, by adding the Taq 
polymerase only once the cycling temperature is above the primer annealing temperature or 
by using chemically modified polymerases that have been modified to be only activated at 
high temperatures, such as Go Taq hot start polymerase (Promega, USA), One Taq hot start 
DNA polymerase (NEB, England), Maxima hot start Taq DNA polymerase (Thermo 
Scientific, SA). These enzymes require a period at a high temperature (~95°C) to destabilise 
the protective structure and release the polymerase (Henegariu et al., 1997, Le et al., 2009). 
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Similarly, some work has been done to elucidate the effect of modifying the dNTP’s structure 
to only work once heat- activated.  The hot start dNTP’s such as CleanAmp dNTP’s (TriLink, 
USA) are also chemically modified with a thermolabile 3′-tetrahydrofuranyl (THF) which 
ensures that dNTP’s remain inactive until high temperature of thermo cycling, then is 
released to begin the PCR (Koukhareva et al., 2009).  
 
This prevents the interaction of primers at ambient temperature that could results in primer 
dimerization, particularly in multiplex PCR where there are many different primers. 
Therefore, using the hot start dNTP’s is also suggested to improve multiplex PCR efficacy 
without many alterations which would be required when optimizing (Koukhareva et al., 
2009, Le et al., 2009). Allele-specific multiplex PCR is a good technique which allows 
amplification of different target sequences of DNA. This allows simultaneous analysis of 
multiple DNA sequences in a single PCR reaction, crucial for detecting genetic mutations and 
deletions. This technique requires extensive optimisation to ensure that all primers involved 
in multiplex PCR are able to work under one PCR condition and cycling.   
 
 
1.5 AIMS AND OBJECTIVES  
 
The aim of the study was to develop a novel diagnostic screening assay for rapid and cost-
effective detection of 7 TERT and 4 TERC mutations that are specifically associated with IST 
failure in AA patients. 
 
The first objective of this study was to create a range of positive controls by site-directed 
mutagenesis PCR to generate separate amplicons containing a single mutation that would be 
cloned into a plasmid vector to develop the assay.  
 
The second objective was to develop a multiplex assay, preferably in a single PCR reaction 





  MSc Medicine: Haematology 
27 
 
CHAPTER TWO: GENERATION OF TERT AND TERC MUTATIONS FOR ASSAY 
DEVELOPMENT 
 
2.1 INTRODUCTION  
 
As described in Chapter 1, AA patients fail to produce sufficient haematopoietic cells due to 
a depletion of stem cells (Young et al., 2000; Gordon-Smith et al., 2001; Dokal and Vulliamy 
et al., 2003).  One of the disease mechanisms responsible for this depletion is a defective 
telomerase enzyme complex, which results in premature apoptosis of the affected stem cells 
(Young et al., 2000).  Mutations in both TERC and TERT, the key components of the 
telomerase complex have been shown to be responsible for this defect in many AA patients 
(Yamaguchi et al., 2005; Vulliamy et al., 2007; Calado et al., 2008; DU et al., 2009). These 
mutations include:  deletions TERC53 and TERC110, and single polymorphisms TERC178 
and TERC180 in the intron-less TERC gene and single/duplex base polymorphisms of TERT 
at positions GC763TA (TERT202) and C1393T (TERT412) in exon 2, G1570A (TERT694) 
and C15735T (TERT704) in exon 5, A26461G (TERT846) in exon 9, T39644C (TERT1015) 
and G40650A (TERT1090) in exon 14 and exon 15, respectively (details given in Table 1.1) 
(Greenwood et al., 2003; Yamaguchi et al., 2005; Marrone et al., 2007; Vulliamy et al., 
2007; Calado et al., 2008; DU et al., 2009).  Patients with these specific mutations do not 
respond to the standard IST administered to AA patients, due to this alternative disease 
mechanism (Young et al., 2006, Marrone et al., 2007; Calado et al., 2008) and thus it is 
essential to detect these mutations early in the diagnostic process.  
 
In order to develop a diagnostic assay, it is necessary to have positive mutant controls. AA is 
a rare disease and less than 40% of patients have a single mutation in one of these genes 
(Young et al., 2000; Calado et al., 2009). The positive mutant controls must therefore be 
artificially generated for use in the assay, since the likelihood of finding patients harbouring 
mutations is low. Hence, the first aim of our study was to generate in vitro positive controls 
of the relevant TERC and TERT mutations, which would then be used to develop the 
diagnostic assay (described in Chapter 3). The strategy was to generate these TERC and 
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PCR primers were designed which contained each of the desired mutations separately. These 
were used to amplify the desired amplicon from human wild type (WT) genomic DNA. In 
this way individual mutations were introduced into the amplicons. To ensure pure mutant 
populations and the ability to generate large quantities as positive controls, amplicons were 
cloned into the pGEMT-Easy plasmid vector.  In order to demonstrate the process of creating 
TERC and TERT mutants,    
 
 
 2.2 MATERIALS AND METHODS  
 
2.2.1 Site-directed mutagenesis (SDM) primers  
The primers for TERC and TERT mutants were designed using Primer3 software, ensuring 
minimal self-complimentary and hairpin formation.  These mutagenic primers were longer 
(25-30 bases) than standard PCR primers to ensure a reasonable 3’ clamp after the mutated 
bases and sufficient 5’ sequence to allow development of primers for the diagnostic assay 
(Chapter 3).  Primers were checked for specificity against the human genome using NCBI 
blast, to ensure no non-specific binding.  All primers were generated at the University of 
Cape Town (Department of Molecular and Cell Biology) and are shown in Table 2.1 below.  
 
Table 2.1: SDM primers to produce TERC and TERT mutations and deletions  
 
$
: Primers used to generate mutants of TERC and TERT are named according to their mutations.  
*
: Positions of deleted bases are underlined in red. 
#
: Base substitutions are indicated in red.   
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2.2.2 Genomic DNA preparation 
Peripheral blood (EDTA, 5ml) was collected from a healthy individual with informed consent 
(approved by the Faculty of Health Sciences Research Ethics Committee, University of Cape 
Town -HREC REF: 131/2011).  A concentrated white cell buffy layer was obtained by 
centrifugation of the sample at 2500 rpm for 10 minutes and the DNA from this layer was 
extracted using the QIAmp
® 
DNA blood mini kit (Qiagen, USA). Briefly, 200μl of the buffy 
layer was mixed with proteinase K (4U/mg) to degrade proteins, RNAse A (10mg/ml) to 
degrade RNA and 200μl lysis buffer (contained 5% SDS and low pH). This solution was 
incubated at 56⁰C for 10 minutes to aid cell lysis.   
 
Thereafter 200μl of ethanol was added to the sample to dehydrate the DNA (aids in silica 
binding) before loading onto the silica QIAamp
®
 mini spin column, via centrifugation (8000 
rpm for 1 minute). The bound DNA was washed sequentially with two buffers (AW1 and 
AW2) to eliminate contaminants (proteins and salts) (500μl each buffer, 8000 rpm for 1 
minute).   Residual wash buffer was removed by a final centrifugation at 14 000 rpm for 1 
minute. The DNA was finally eluted from the silica column by incubation with 200μl 
nuclease-free water at room temperature for 1 minute followed by centrifugation at 8000 rpm 
for 1 minute.  The concentration of DNA was quantified using a UV-Vis Spectrophotometer 
Nano-Drop 2000 (Thermo Scientific, USA) and stored at -20⁰C.    
 
2.2.3 SDM PCR for generation of TERC and TERT mutants  
PCR reactions for the generation of each mutant consisted of the following in a final reaction 
volume of 25μl: 1X Green GoTaq
®
 Flexi Buffer (Promega, USA), 2U GoTaq
®
 Hot Start 
Polymerase (Promega, USA), 0.8mM dNTPs, 2mM magnesium chloride (Promega, USA), 
25pmol  of each forward and reverse primer (Table 2.1), and 40ng human genomic DNA. 
The PCR cycling conditions were as follows: polymerase activation and initial genomic DNA 
denaturation at 95°C for 4 minutes, followed by 35 cycles of template denaturation at 94°C 
for 30 seconds, primer annealing at a range of 55°C- 65°C for 30 seconds, and extension at 
72°C for 90 seconds. A final extension step of 72°C for 8 minutes was included to ensure 
amplicon completion. PCR products were resolved by agarose gel electrophoresis, using a 
2% TAE agarose gel and electrophoresis in 1X TAE buffer (40mM Tris, 20mM acetic acid, 
1mM EDTA) at 75 volts for ±1.5 hours. The DNA amplicons were stained with ethidium 
bromide (0.5 μg/ml) (Sigma, USA) and visualized under UV light using the UV doc system 
(UVItec, UK).  
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2.2.4 Purification of PCR products 
Following successful amplification, each relevant amplicon band was excised from the gel 
and purified using the QIAquick
®
 PCR purification kit (Qiagen, USA) following the 
manufacturer’s instructions. Briefly, the excised gel fragment was dissolved in 3 gel volumes 
of buffer QG, by incubation at 50°C for 10 minutes. To aid in binding of the DNA to the 
silica column, one gel volume of isopropanol (Sigma, USA) was added and the solution 
loaded onto the QIAquick
®
 Minielute column followed by centrifugation at 13000rpm for 1 
minute.  
 
The bound DNA was washed with 500µl of buffer QG (13000 rpm, 1 min), followed by a 
second wash with 750μl of buffer PE (to remove salts) (13000rpm, 1 min). Residual ethanol 
from the PE buffer was removed via a second centrifugation (13000rpm, 1 minute). Finally 
the amplicon DNA was eluted with 10µl nuclease-free water and quantified using a UV-Vis 
Spectrophotometer Nano-Drop 2000 (Thermo Scientific, USA) and stored at -20°C.  
 
2.2.5 Cloning of PCR products into pGEMT-Easy 
2.2.5.A: Ligation  
Purified PCR products (section 2.2.4) containing the relevant mutations were cloned into the 
pGEMT-Easy bacterial vector using T4 DNA ligase (Promega, USA). A vector: insert ratio 
of 1:3 was used for all ligation reactions, with 50ng of pGEM
®
T-Easy vector being used in 
each reaction. To calculate the relevant amount of insert (purified PCR product) the following 
formula was used:   [(50ng of vector × kb size of insert) ÷ (kb size of vector) × ratio of 3 = 
Xng of insert required for the reaction] (Promega Bio Math online, 
http://www.promega.com/techserv/tools/biomath/calc06.htm). The ligation reaction was 
performed according to the manufacturer’s recommendations (Promega, USA), with a 10µl 
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2.2.5.B: Transformation and small scale DNA preparation 
An aliquot of the ligation reaction (2µl) was mixed with 100μl of calcium-chloride prepared 
competent Escherichia coli (E. coli) (DH5 Alpha strain) (Dagert et al., 1979) and incubated 
on ice for 25 minutes.  Thereafter the samples were subjected to heat shock by incubating the 
cells at 45⁰C for 2 minutes and chilled on ice for a further 5 minutes to allow DNA uptake.  
This was followed by the addition of 900μl Luria Broth (LB) bacterial medium and 
incubation for 1 hour at 37⁰C, to allow expression of the enzyme beta-lactamase, responsible 
for resistance to ampicillin in the transformed bacteria, before the selection pressure was 
applied. An aliquot of the transformation mix (100µl) was plated onto LB-Agar plates 
containing 50μg/ml ampicillin (Sigma-Aldrich), 40μg/ml 5-bromo-4-chloro-3-indolyl-beta-
D-galactopyranoside (X-gal) (Sigma-Aldrich) and, 0.1mM isopropyl beta-D-
thiogalactopyranoside (IPTG) (Sigma-Aldrich) and incubated overnight (16 hours) at 37⁰C.  
White bacterial colonies, indicating successful transformation were selected and cultured in 
5ml LB media containing ampicillin 50μg/ml overnight at 37⁰C.    
 
Plasmid DNA was extracted from these O/N cultures using the Nucleobond
® 
Xtra maxi-prep 
kit (Macherey-Nagel, USA), following manufacturer’s instructions with modification. 
Bacteria from 2ml of O/N culture were harvested by centrifugation (6000rpm, 15 minutes, 
4⁰C) and the supernatant discarded. Bacterial cell pellets were resuspended in 300μl buffer 
N1 containing RNase A, followed by an addition of 300μl buffer N2 and incubation at room 
temperature for 5 minutes to allow cell lysis. Pre-cooled buffer N3 (300µl) was added to 
precipitate the proteins (5 minutes, on ice), and then the sample was centrifuged (14 000rpm, 
30 minutes, 4⁰C) and the clear supernatant transferred to a new tube. Isopropanol (0.7 
volumes) was added to precipitate the DNA, followed by immediate centrifugation 
(14 000rpm, 10 minutes, 4⁰C) and washing of the DNA pellet with 1ml 70% ethanol to 
remove salts (14 000rpm, 5 minutes, 4⁰C). The plasmid DNA was resuspended in 50µl 
nuclease-free water (50µl) and then digested with restriction enzymes to verify successful 






  MSc Medicine: Haematology 
32 
 
2.2.5.C: Analysis of clones using Restriction Enzyme digestion  
To confirm the cloning of amplicons into the pGEM
®
T-Easy vector, the purified plasmids 
(section 2.2.5.B) were digested with EcoR1 (Promega, USA) to release the amplicon insert 
from the vector.  Each  restriction enzyme digestion reaction (20μl) contained the following, 
1X restriction enzyme buffer (Promega, USA),  1µg plasmid DNA, 10U EcoR1 (Promega, 
USA), and nuclease-free water (Qiagen, USA). The restriction enzyme digestion mix was 
incubated at 37⁰C for 2 hours and the digested DNA was resolved on a 2% agarose TAE gel 
(75V, 1.5 hours).  The restricted products were stained with ethidium bromide (0.5μg/ml) and 
visualized under UV light using the UV doc system (UVItec, UK).   
 
2.2.5.D: Large scale plasmid preparation 
After the restriction enzyme digests confirmed successful cloning of inserts (section 2.2.5.C), 
corresponding bacterial cultures were inoculated in 50ml of LB media containing 50μg/ml 
ampicillin and grown O/N at 37˚C, with vigorous shaking.  Large-scale, high quality plasmid 
DNA was extracted from the cultures using the Nucleobond
®
 Xtra Maxi-prep kit (Macherey-
Nagel, USA), following manufacturer’s instructions. Briefly, overnight cultures (40ml) were 
collected using centrifugation (6000rpm, 15 minutes, 4⁰C) and the supernatant removed.  
Bacterial cell pellets were resuspended in 12ml buffer S1 (RNase A added), followed by an 
addition of 12ml buffer S2 and incubation at room temperature for 5 minutes to allow cell 
lysis.  
 
Pre-cooled buffer S3 (12ml) was added to precipitate the proteins (5 minutes, on ice), 
followed by filtering to remove cell debris and proteins through a filter paper flow-through 
system. The cleared lysate was loaded onto a hydrated column and the bound DNA was 
washed twice with buffer N3 (2X 32ml) to remove residual salts.  The DNA was finally 
eluted in 15ml buffer N5 and precipitated using 0.7 volume isopropanol. The precipitated 
DNA was collected via centrifugation (14000rpm, 30 minutes, 4⁰C) and washed with 70% 
ethanol  to remove residual salts (14000rpm,  10 minutes, 20⁰C)..  The plasmid DNA was 
reconstituted by dissolving the pellet in nuclease-free water (Qiagen, USA).  Purity and 
quantity of DNA was determined by UV-Vis Spectrophotometer Nano-Drop 2000 (Thermo 
Scientific, USA) and stored at -20°C.  
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2.2.6 Sequence analysis of DNA fragments 
The TERC and TERT purified PCR products and plasmid constructs were sequenced using 
the ABI Prism BigDye
®
 Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems, USA). 
Each sequencing reaction consisted of BigDye
®
 mix (0.25X), sequencing buffer (0.3X), 
3.2pmol of the relevant reverse primer (Table 2.1), 10ng of each individual mutant PCR 
product or 10ng plasmid construct and nuclease-free water to a final volume of 10μl. The 
cycling conditions for the sequencing reaction were as follows: 96°C for 15 seconds, 30 
cycles at 96°C for 15 seconds, 50°C for 15 seconds and 60°C for 4 minutes. Fragments were 
analysed on an ABI3120 genetic analyser (Applied Biosystems, USA) at the DNA Sequencer 
Unit, Stellenbosch University. The sequences were analysed using the Chromas Lite software 
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2.3 RESULTS  
 
2.3.1 Experimental design 
The mutations that were selected for inclusion in the proposed diagnostic assay were based 
on their association with a telomerase malfunction and confirmed association with IST failure 
in AA patients (Yamaguchi et al., 2005, Vulliamy et al., 2007, DU et al., 2009). Table 2.2 
shows the list of clinically relevant mutations chosen for this study. 
 
 
Table 2.2: Summary of TERC and TERT mutations used in this study 
 
*
:  The TERC (light red shaded) and TERT mutants 
 
Ω
: DNA based change refers to specific DNA sequence on the NCBI database with accession number NC 
000005 for TERT and NR 001566 for TERC.  
€: Region represents the part where mutations occur on the TERC gene and TERT gene and  exon depicts the 
position a mutation is found in the DNA sequence of TERT gene and  N/A refers to not applicable. 
β
: Amino acid change shows the modification in the protein synthesized due to DNA base changes in the 
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To create the desired controls for detection of these specific mutations, point mutations and 
deletions were introduced into amplicons using forward primers containing the various 
mutations (SDM). TERC is a short intron-less gene, encoding the RNA template (451bp) for 
telomerase (Yamaguchi et al. 2003), making it possible to use a common reverse primer 
(TCR) with four mutated forward primers (TC53, TC110, TC178 and TC180) to generate the 
desired amplicons. The specific SDM primers are listed in Table 2.1 (section 2.2.1 of the 




Figure 2.1: Binding positions of the SDM primers used to generate TERC mutants.  
Nucleotide sequence of TERC (from position 1-421), NCBI database NR 001566, used to generate mutants.   
The colour-coded arrows indicate the location (5' - 3' orientation) of the SDM primer sets (Table 2.1), used for 
generation of mutants TERC53, TERC110, TERC178 and TERC180. The red bold nucleotides show an area 
where a deletion is generated and black bold indicates where a single base change is introduced. The purple line 
indicates the common reverse primer for all forward primers.  
 
 
TERT is a large 45kb gene, comprising 16 exons. The clinically relevant mutations chosen for 
the study (Table 2.2) were spread over 5 exons, requiring multiple forward/reverse primer 
sets to amplify the relevant areas. Figures 2.2 and 2.3 show the binding positions of the 
various primer sets, which included the specific SDM forward primer and an exon-specific 
reverse primer (details given in Table 2.1) to allow the creation and amplification of all the 
mutant products.  Some exons contained more than one relevant mutation, which then 
allowed a common reverse primer for the generation of those mutants (i.e. exons 2 and 5).  
Due to their close proximity, amplification of the exon 14 and 15 mutations was also 
achieved with a common reverse primer.   




Figure 2.2: Binding positions of SDM primers for the amplification of TERT mutations in exons 2 and 5  
Nucleotide sequences of exon 2 (682- 1760) and exon 5 (15575- 16042) of the human TERT gene (NCBI 
database with accession number NC 000005), which was used to generate TERT202, TERT412, TERT694 and 
TERT704 mutants.  The colour-coded arrows indicate the binding positions (5' - 3’ orientation) of the primers 
that were used to generate each corresponding mutation (sequences given in Table 2.1). The bold nucleotides 
show an area in the WT sequence where a mutation was introduced to generate the desired mutant.  The purple 
line indicates the common reverse primer on the exon 2, while the green line shows the common reverse primer 













Figure 2.3: Binding positions of SDM primers for the amplification of TERT mutations in exons 9, 14 and 
15  
Nucleotide sequences of exon 9 (26412- 26710), exon 14 and 15 (39611- 40850) of the human TERT gene 
(NCBI database with accession number NC 000005), which was used to generate TERT846, TERT1015 and 
TERT1090 mutants.  The colour-coded arrows indicate the binding position (5' - 3’ orientation) of the primers 
that were used to generate each corresponding mutation (sequences given in Table 2.1). The bold nucleotides 
show an area in the WT sequence where a mutation was introduced to generate the desired mutant.  The brown 
line indicates the reverse primer on the exon 9 and the line blue line shows the common reverse primer on the 
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2.3.2 Creation of SDM TERC mutant amplicons  
DNA from the blood of a healthy individual was isolated (described in section 2.2.2) and 
used as a template with the specific SDM primers listed in Table 2.1 to amplify fragments 
containing the desired mutations.  For the generation of all TERC mutant amplicons, a 
temperature gradient of 55⁰C- 64⁰C was used to identify the most appropriate annealing 
temperature to generate a specific, single and well-amplified product (where possible) that 
could be excised and used for subsequent sequence analysis and cloning into the pGEMT-
Easy vector. PCR reactions were performed as described in section 2.2.3, with TERC53  
SDM amplicon created with primers TC53 and TCR (Table 2.1)  (544bp),  TERC110 SDM  
with primers TC110 and TCR  (470bp),  TERC178 SDM amplicon with primers TC178 and 
TCR (445bp) and TERC180 SDM amplicon with primers TC180 and TCR (450bp).  A 
reagent blank, negative control (NC) was also included in each PCR experiment to monitor 
contamination. Figure 2.4 shows the results analysis of all 4 mutants: TERC53 SDM 












Figure 2.4: Electrophoretic analyses of annealing temperature gradient PCR for TERC mutant 
amplifications using SDM primers  
SDM TERC amplicons generated using specific SDM primers. A temperature gradient was used for the 
annealing temperature to determine the most appropriate amplification conditions. This is a photograph showing 
the amplicons resolved a 2% agarose TAE gels, stained with ethidium bromide and visualized with UV light. 
Lane MW: low molecular weight ladder (NEB), lane NC: negative control and lane numbers refer to the 
annealing temperature used. Panel A: TERC53 amplicons, lane 1: 58°C, 2: 60°C, 3: 62°C, 4: 63°C, 5: 64°C;  B: 
TERC110,  lane 1: 58°C, 2: 60°C, 3: 61°C, 4: 63°C, 5: 64°C;  C: TERC178,  lane 1: 55°C,  2: 56°C, 3: 57°C, 4: 
58°C,  and 5: 60°C;  and D: TERC180, lane 1: 59 °C, 2: 61°C, 3: 63°C,  and 4: 64°C.     
 
 
For TERC110, TERC178 and TERC180, single amplicons of the expected sizes were clearly 
observed with the following annealing temperatures yielding optimal results: 64⁰C for 
TERC110 (Figure 2.4.B), 56⁰C for TERC178 (Figure 2.4.C), and 63⁰C for mutant TERC180 
(Figure 2.4.D).  However, the amplification of TERC53 consistently produced a non-specific 
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To eliminate non-specific banding, various approaches were undertaken including increasing 
the annealing temperature range, magnesium chloride titration (1.5mM- 3mM) and 
decreasing the PCR extension time.  Unfortunately the amplification of TERC53 persisted in 
yielding non-specific products (results not shown). Products were again created and amplified 
using the most appropriate annealing temperatures as indicated, with TERC53 being 
amplified at 64⁰C. The expected sized amplicons were excised and purified as described in 
section 2.2.3 and 2.2.4, and analysed for the presence of mutations via sequence analysis 
using the TCR primer (section 2.2.6).  Sequences were aligned to the WT human TERC gene 
(NCBI database, accession number: NR 001566) and two examples of this analysis are shown 
in Figure 2.5. This figure shows the sequence alignment of the TERC53 SDM amplicon (and 
the creation of the desired deletion of bases 53-87) with its corresponding WT human TERC 
sequence (panel A), as well as SNP TERC178 (G178A) (panel B). All the TERC mutations as 




Figure 2.5: Sequence analysis of TERC53 and TERC178 SDM products  
 Panel A: Alignment of TERC53 SDM amplicon (reverse complement sequence) and WT TERC gene (REF 
TERC) (NCBI NR 001566) from position (1- 292) indicating the deleted region 53- 87 in the TERC53 sequence.   
Panel B: Sequencing chromatogram of TERC178 SDM amplicon (reverse complement sequence) of PCR 
product (128-187bp) showing the mutated region (G178A).   
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2.3.3 Creation of mutant TERT amplicons 
The DNA from a healthy individual, isolated as described in section 2.2.2, was used as a 
template with the specific SDM primers listed in table 2.1 to produce PCR amplicons 
containing the desired TERT mutations.  As was done for the TERC mutants, an annealing 
temperature gradient was performed to identify optimal conditions for the generation of a 
single specific fragment, without non-specific amplicons.  PCR reactions were performed as 
described in section 2.2.3 (using a temperature gradient of 55ºC- 64ºC for the annealing step) 
with mutant TERT202 amplified with primers TT202 and TT-exon2R (Table 2.1) (900bp),  
TERT412 amplified with primers TT412 and TT-exon2R (378bb),  TERT694 amplified with 
primers TT694 and TT-exon5R (356bp), mutant TERT704 amplified by primers TT704 and 
TT-exon5R (323bp), TERT846 amplified with primer TT846 and TT-exon9R (243bp), 
TERT1015 amplified with primers TT1015 and TT-exon14-15R (1224bp) and mutant 
TERT1090 amplified with primers TT1090 and TT-exon14-15R (221bp). To control for DNA 
contamination in the PCR reagents, a reagent blank/negative control (NC) was also 
performed in each experiment.  
 
Single specific bands, of the correct size were amplified for mutant fragments TERT412, 
TERT694, TERT704, TERT1015 and TERT1090 at all annealing temperatures used. Figure 









Figure 2.6:  Electrophoretic analyses of annealing temperature gradient PCR for TERT mutant 
amplifications using SDM primers.  
SDM TERT amplicons generated using specific SDM primers. The photograph shows the amplicons resolved on 
2% agarose TAE gels, stained with ethidium bromide and visualized with UV light. Lane MW: low molecular 
weight ladder (NEB), lane NC: negative control.  Lane numbers in each panel refer to the annealing temperature 
used.  Panel A: TERT412 SDM amplicons, lane 1: 56°C, 2: 58°C, 3: 60°C, 4: 62°C, 5: 64°C;  B: TERT694,  lane 
1: 58°C, 2: 60°C, 3: 64°C, 4: 64°C;  C: TERT1090,  lane 1: 56°C,  2: 58°C, 3: 60°C, 4: 64°C;  and D: 
TERT1015, lane 1: 59 °C, 2: 61°C, 3: 63°C,  and 4: 64°C.     
 
 
In the case of mutants TERT202 and TERT846, multiple bands were generated at all 
annealing temperatures used, and although there was an increase in amplification of the band 
of the correct size as the annealing temperature was gradually increased, non-specific 
fragments were also consistently amplified. Further optimization was carried out to try and 
improve specific amplification of these two mutants by performing a magnesium chloride 
titration ranging from 1- 3mM. However, this did not improve the result significantly (results 
not shown).  
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Figure 2.6 above shows examples of troubleshooting the non-specificity experienced when 
amplifying mutants of TERT202 and TERT846. In addition to temperature gradient and 
magnesium chloride titration, a decrease of PCR extension time was also performed but the 




Figure 2.7: Electrophoretic analyses of annealing temperature gradient PCR for TERT202 and TERT846 
mutant amplifications using SDM primers. 
SDM PCR products were created using specific SDM primers. The above photograph shows the amplicons 
resolved on 2% agarose TAE gels, stained with ethidium bromide and visualized with UV light. A temperature 
gradient was used for the annealing temperature to identify the most suitable conditions for amplification.  Lane 
MW: low molecular weight ladder (NEB), lane NC: negative control.  Lane numbers refer to the annealing 
temperature used. Panel A: TERT202, Panel B: TERT 846.  Lanes showing annealing temperatures used.  Panel 
A: TERT202 SDM amplicons, lane 1: 55°C, 2: 56°C, 3: 58°C, 4: 59°C, 5: 60°C, 6: 61°C, 7: 62°C, 8: 63°C; 9: 
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The SDM PCR reactions were repeated using the following specific annealing temperatures: 
60°C for TERT412 and TERT1015, 62°C for TERT1090 and TERT704, and 64°C for 
TERT694. For TERT202 and TERT846, SDM PCR reactions were repeated using an 
annealing temperature of 65°C, which displayed the least non-specific amplification. All 
SDM amplicons were excised and purified as described in section 2.2.4 and sequenced as 
described in section 2.2.6 to check for the creation of the specific mutations via sequencing 
analysis. The TERT202 and 412 amplicons were sequenced using the reverse primer TT-
exon2R (Table 2.1), TERT694 and 704 with primer TT-exon5R (Table 2.1), TERT846 with 
primer TT-exon9R (Table 2.1) and TERT1015 and 1090 with TT-exon14-15R (Table 2.1).  
 
To verify and confirm the presence of the desired mutations before cloning into pGEM
®
T-
Easy, the sequencing products were aligned using BIOEdit to the reference human TERT 
gene (NCBI database with accession number: NC 000005). Figure 2.8 below shows 
sequencing analysis of TERT202 SDM product and TERT846 SDM product as example of 









Figure 2.8: Sequence analysis of TERT202 and TERT846 SDM products  
 Panel A: Alignment of TERT202 SDM amplicon (reverse complement sequence) and WT TERT gene (NCBI 
database with accession number: NC 000005) from position (301- 600) indicating the mutations GC>TA in the 
TERT202 sequence. Panel B: Alignment of TERT846 SDM amplicon (reverse complement sequence) and WT 
TERT (exon 9) gene (NCBI database with accession number: NC 000005) from position (1- 300) indicating the 
base change A>G in the TERT846 sequence compared to the reference gene.  
 
 
2.3.5 Cloning of SDM PCR amplicons TERC and TERT into the pGEMT-Easy plasmid 
Following sequence confirmation, the SDM PCR products described above (for all TERT and 
TERC mutations) were cloned into pGEM
®
T-Easy as described in section 2.2.5.  Amplicons 
were ligated at a ratio of 3:1 to pGEM
®
T-Easy and transformed into competent E. coli.  
White colonies (3-5) were selected on X-gal/IPTG plates; small scale cultures were 
established and plasmid DNA was prepared via small-scale plasmid preparations (section 
2.2.5.B). To confirm the cloning of the SDM amplicon into the vector, restriction enzyme 
digests were performed on all of the selected clones (TERC and TERT), using EcoR1 (section 
2.2.5.C).  
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The multiple cloning site of the pGEM
®
T-Easy plasmid is flanked by recognition sites for 
EcoRI, which can be used to release the cloned amplicon (with 122bp of added vector 
sequence). Figure 2.9.A shows the results of several digests. Figure 2.9.A shows the 
successful digestion of plasmid DNA from a single TERT202-pGEMT-Easy prospective 
clone, showing the production of two fragments (lane 2) one representing the TERT202 SDM 
PCR product together with a small piece of plasmid (1022bp) another for pGEMT (2893bp).  
The plasmid from a single clone potentially containing TERC180 SDM product also gave the 
expected fragment sizes of  567bp for TERC180 SDM PCR product together with a small 
piece of pGEM
®
T) and 2893bp for pGEMT-Easy plasmid. 
 
Figure 2.9.B represents the restriction enzyme digestions of plasmid DNA from clones of 
TERT846 SDM product and TERT1090 SDM. From the TERT846 SDM clone two fragments 
(lane 1 and 2) were produced, one indicating the TERT846 SDM product (365bp) with 
flanking pGEMT-Easy sequence and another corresponding to linearized pGEMT-Easy 
plasmid (2893bp), while TERT1090 SDM clone also produced two fragments, one 
representing TERT1090 SDM product (343bp) with flanking pGEMT-Easy sequence and the 
other corresponding to linearized pGEMT-Easy plasmid (2893bp).  
 
 




Figure 2.9: Electrophoretic analyses of restriction enzyme digests using EcoRI of TERC 
and TERT clones.    
Restriction enzyme digests of TERC and TERT clones with EcoR1 to release the cloned SDM products from the 
pGEMT-Easy. Digested fragments were resolved on 2% agarose TAE gels, stained with ethidium bromide and 
visualized over UV light. Lane MW: molecular weight ladder (NEB).  Panel A: lane 1: TERC180C with 
flanking vector sequence (567bp) and linearized pGEMT backbone (2893bp), lane 2: TERT202C (900bp) with 
flanking vector sequence (1022bp) and pGEMT-Easy linearized backbone (2893bp).  Panel B: lane 1 and 2: 
TERT846C with flanking vector sequence (365bp), and lane 3 and 4: TERT1090C with flanking vector sequence 
(343bp), and all four planes also contain the linearized pGEMT backbone (2893bp).  
 
 
Selected clones of TERC and TERT from each cloning experiment were used to perform a 
large scale DNA preparation as described in section 2.2.5.D. Although the SDM PCR 
products were sequenced before cloning, there remained a small possibility that non-mutated 
or non-specific amplicons were present within the purified products. While restriction 
enzyme digestion confirmed the cloning of the correct sized amplicon, it did not reveal the 
mutational status of the cloned amplicons. Since cloning involves the expansion of a clone 
containing a single amplified product, it was essential to confirm that the correct mutated 
product had been cloned before it could be used as a positive control for the assay 
development.  
 
  MSc Medicine: Haematology 
48 
 
Therefore, purified DNA from the plasmid constructs was sequenced according to section 
2.2.6 and the sequences aligned using BIOEdit to either the human TERC DNA reference 
sequence (NCBI database with accession number: NR 001566)  or the human TERT DNA 
reference sequence (NCBI database with accession number: NC 000005). Figure 2.10.A 
shows the result of an alignment of the cloned TERC110 SDM sequence with the WT human 
TERC gene. The presence of the relevant mutation is clearly seen.  
 
 Figure 2.10.B shows the sequence chromatogram of TERC180 cloned into pGEM
®
T-Easy, 
and again, the relevant mutation is present. These results are representations of how all of the 
cloned TERC mutants were verified.  Similarly, Figure 2.11.A shows the results of an 
alignment of the cloned TERT412 SDM sequence with the WT human TERT gene. The 
presence of the mutation of interest is confirmed. Figure 2.11.B shows the sequence 
chromatogram of TERT704 cloned into PGEM
®
T-Easy vector, once more, the desired 





Figure 2.10: Sequence analysis of TERC110C and TERC180C cloned SDM products.  
 Panel A: Alignment of TERC110C SDM amplicon sequence (reverse complement sequence) cloned into 
pGEMT-Easy and WT human TERC gene (NCBI database with accession number: NR 001566) from position 
(91- 400bp) indicating the deletion (del110-113, TGAC) in the TERC110C sequence. Panel B: sequence 
chromatogram of TERC180C (reverse complement sequence) compared to the WT human TERC gene (NCBI 
database with accession number: NR 001566) showing the mutations (SNP, C>T) in the TERC180C sequence.   
 




Figure 2.11: Sequence analysis of TERT412C and TERT704C cloned SDM products. 
 Panel A: Sequence chromatogram of TERT412C (reverse complement) compared to the WT human TERT gene 
(NCBI database with accession number: NC 000005) showing the based change (C>T) in the sequence of 
TERT412C. Panel B: sequence alignment of TERT704C cloned into pGEMT-Easy (reverse complement 
sequence) and WT human TERT gene (NCBI database with accession number: NC 000005) from position (101- 
384bp) indicating a mutation (SNP, C>T) in the TERT704C sequence.    
 
 
Following this sequence confirmation the clones were then used for all further experiments 
and were named according to either the position of the DNA base change (compared to the 
wild type gene), as used for the TERC clones or the resulting amino acids substitution 
position in the TERT clones (compared to the wild type protein sequence). Hence these 
plasmid mutants were referred to as TERC53C, TERC110C, TERC178C and TERC180C for 
TERC gene mutations and TERT202C, TERT412C, TERT694C, TERT704C, TERT846C, 
TERT1015C and TERT1090C for TERT gene mutations. Table 2.3 gives details on the 
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Table 2.3: List of plasmids containing TERC and TERT mutants 
 
€
: Cloned SDM products of TERC and TERT into pGEMT-Easy 
£
: Primers used to generate SDM products 
¥
:  SDM PCR product sizes. 
β
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2.4 DISCUSIONS AND CONCLUSIONS 
 
AA is a life threatening disease which may cause early deaths to the affected patients (Young 
et al., 2000, Gordon-Smith et al., 2001). Detecting the cause of this disease and the 
mechanism involved in the disease development is important to be determined before patients 
are directed to the therapy. This is because some AA patients (approximately 40%) do not 
respond to the main chemotherapy, IST therapy (Young et al., 2005, Spellman et al., 2012).  
The primary disease mechanism of AA is an attack of haematopoietic stem cells by T-
leucocytes with an approximate of 60% of patients who respond to IST, while  40% of AA 
patients remain non-responsive (Young et al., 2006; Affable et al., 2011). Mutations in the 
telomerase complex, specifically from two key components of the complex, TERC and TERT, 
have been indicated as the main cause of the secondary disease mechanism of AA.  This 
secondary disease mechanism is caused by ineffective of the telomerase complex to 
synthesize telomeres, which signal the cell to apoptosis to avoid genetic instability after 
chromosomes not being capped properly. Patients who harbor the mutations on the 
telomerase complex do not respond to IST therapy and thus it is essential to screen the 
patients prior to treatment decisions (Calado et al., 2009, Du et al, 2009).  
 
Not all mutations of the telomerase complex associated with AA have been directly linked to 
IST failure (Yamaguchi et al., 2005; Vulliamy et al., 2007; Calado et al., 2008; DU et al., 
2009). This study was designed to develop an assay allowing for the rapid detection of those 
mutations which have been specifically linked to IST failure amongst AA patients, so that the 
assay has a direct clinical impact. Currently, telomerase (TERC and TERT) mutations are 
detected via sequencing which involves intensive laboratory work, including the 
amplification and sequence analysis of numerous exons of the TERT gene and the whole 
TERC genes. Therefore an assay involving multiplex PCR would allow rapid and specific 
detection of these mutations with results generated in one day. This will allow early 
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Usually, diagnostic assays are developed using positive controls that have been taken from 
the patient population. These controls allow for the validation of the assay, including the 
determination of reproducibility, sensitivity and accuracy. Due to the fact that AA is a rare 
disease, these positive controls are not readily available and presently no commercial vendor 
supplies them. Thus, in order to develop an assay to detect these important clinically relevant 
mutations it was necessary to artificially create them. The approach was to design primers 
with mutation (SDM primers) that would produce a PCR product with containing a desired 
mutant.    
 
Designing of SDM primers proved to be problematic in some instances as they had to be long 
enough to allow homologous annealing on either side of the mutation, but also to allow for a 
second round of specific amplification during the actual diagnostic assay. Furthermore, due to 
the nature of the DNA sequence having certain bases dominating on the sequence, 
positioning of the primers was limited as some sequences dominated either AT or GC 
contents. Therefore in most cases the primers failed the standard criteria for use in a 
successful PCR reaction. These parameters are 60% GC content, 18-22bp primer, an ideal 
annealing temperature (Tm) between 55ºC - 65ºC, hairpin formation and primer-dimer 
formation with the reverse primer. 
 
 Despite the challenges that these primers potentially posed, successful, single SDM 
amplification products were created for the TERC mutants: TERC110 SDM amplicon, 
TERC178 SDM amplicon, TERC180 SDM amplicon using human WT genomic DNA and 
the TERT mutants: TERT412 SDM, TERT694 SDM, TERT704 SDM, TERT1015 SDM and 
TERT1090 SDM.  Using a Go-Taq
®
 hot start DNA polymerase (Promega, USA) minimized 
difficulties which could have been experienced with the PCR setup. It allowed the 
amplification of targets because of its robust activity. Although primer dimers and non-
specific products were experienced on other PCR reactions for mutants production, but most 
of them were created successfully. Despite that when using GoTaq
®
 hot start DNA 
Polymerase (Promega, USA)  the PCR reaction could be setup at room temperature; we took 
precautions to setup all reactions on ice to ensure that all reagents are inactive even if the 
protective antibody on the DNA polymerase would have been disturb and the enzyme was 
released to be readily active. This further allowed the specific amplification of PCR 
amplicons.  
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However, the production of a single specific product for TERC53 SDM amplicon, TERT202 
SDM amplicon and TERT846 SDM amplicon could not be achieved. This could be due to the 
fact that the SDM primer for TERT202 SDM product had two mismatched to create two 
mutations, and therefore could not anneal with strong specificity to a single region in the 
template compared to just a single mismatch for the others. In the case of TERT846 SDM, the 
non-specific products were potentially caused by various reasons, including the fact that the 
primer is long and the presence of primer dimers. It could be possible that synthesized 
primer-dimers became a secondary template in the reaction, allowing primers to further bind 
and produce another product. This could be the possibilities as multiple products were 
experienced with the production of these mutants.  
 
 Non-specific amplification using the TERC53 SDM primer was expected, as it contains a 
large region that is not homologous to the target region. To improve specificity, various 
approaches were conducted, starting with performing magnesium chloride titration ranging 
from (1.5- 3mM), decreasing the number of PCR cycles from 35 to 30 cycles, increasing 
extension time from 90 seconds to 2 minutes. Changing the magnesium chloride 
concentration could potentially improve the specific amplification. Since magnesium is a 
critical co-factor for the Taq DNA polymerase requires being optimal in the reaction, 
therefore low or too high magnesium concentration may lead to ineffective enzymatic activity 
of Taq DNA polymerase.  
 
The magnesium concentration could affect annealing of primers, template and PCR product 
since this may affect the interaction of the enzyme and lowers the activity (Innis et al., 1988). 
In most cases, the extension time and number of cycles during PCR amplification depends 
upon the initial concentration of the template but 90 seconds for extension and 35 cycles are 
usually enough for amplification. Nevertheless, in some cases where at late cycles when 
product concentration exceeds enzyme concentration extended extension time (2 minutes) 
may be helpful to finish product which may be not synthesized completely.  Also decreasing 
cycles may potentially help to reduce non-specific products which may be formed at later 
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But all these attempts were unsuccessful to eliminate non-specific PCR amplification. 
However, despite non-specific products, the correct amplicons were extracted for purification 
and confirmed the desired mutations. Eventually, sequencing of all cleaned SDM products 
confirmed the introduction of the required mutations (SNPs and deletions) into the TERC and 
TERT amplicons. Since all clinically relevant mutations of TERC and TERT were created, to 
ensure pure mutants and the ability to generate large quantities of positive controls, mutations 
amplicons were cloned into the pGEM
®
T-Easy plasmid vector. This significantly increased 
the storage capacity of the mutants and avoids DNA degradation for long term usage.   
 
As the cloned products sizes were already confirmed to be correct during the cloning process 
using restriction digestion. There was still a possibility that during the process the DNA 
sample could be tampered and get degraded after handling with different reagents, and freeze 
and taw. Therefore to ensure that stored cloned SDM PCR products of TERC and TERT were 
still intact and correct, and that only the desired mutations were available in the products. 
Cloned SDM products were sequenced and this proved that all stored mutants were correct 
and can be used on further experiments to develop a diagnostic assay.   
 
In conclusion the first aim of the study was successfully achieved which was to generate the 
clinically relevant mutations in vitro and to clone them in into pGEM
®
T-Easy. This ensured 
that these positive controls can be produced in large quantities, have increased stability and 
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CHAPTER THREE: DEVELOPMENT OF AN ALLELE-SPECIFIC MULTIPLEX 
PCR ASSAY TO DETECT TERC AND TERT MUTATIONS  
 
3.1 INTRODUCTION  
 
The strategy to detect specific TERC and TERT mutations in the DNA of AA patients was to 
use an allele-specific multiplex PCR, where the presence of a mutation would result in the 
amplification of a PCR product. The aim was to develop a single tube allele-specific 
multiplex PCR assay to detect all 4 TERC mutations and another single tube allele-specific 
multiplex PCR assay to detect all 7 relevant TERT mutations. Each single-tube reaction also 
needed to incorporate a control amplification to account for possible problems with DNA 
quality and PCR reagents.  
 
To achieve this ambitious aim, the approach was to first determine a common PCR program 
and reaction mix to allow the amplification of the TERC mutations, but not the WT 
equivalents, using single-plex PCR reactions (i.e: one set of primers and one heterozygous 
mutant template). To this end, the cloned TERC and TERT mutations described in Chapter 2 
were diluted into WT genomic DNA to create more realistic, naturally occurring controls 
(20% mutated allele) and used as positive controls for the assay, while genomic only DNA 
served as the negative control. The primers were then combined to assess the efficiency and 
accuracy of amplification of each of the mutants in a multiplex environment and optimisation 
was performed where necessary. Once the TERC PCR program had been established, single-
plex reactions for the TERT mutations were tested using these conditions and again the 
reactions were optimised, however now limited to reaction components (such as glycerol, 
magnesium chloride). Finally, the primers were combined to try to optimise the amplification 
of each mutant in this multi-primer environment. It must be noted that it is not expected for 
an individual to harbour multiple mutations of the same gene, thus amplification of single 
mutations within this multi-primer environment was primarily tested. Once an assay was 
established, the final objective was to test various aspects of the assay so that it could be 
effectively used in a routine diagnostic environment. This validation required the sensitivity 
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3.2 MATERIALS AND METHODS  
 
3.2.1 Templates for assay development 
3.2.1.A: WT human genomic DNA control (negative control) 
WT human genomic DNA was prepared as described in section 2.2.2 (Chapter 2) to be used 
as a mutation-free negative control. For all PCR assays, a concentration of 40ng/μl of DNA 
was used. 
 
3.2.1.B: Plasmid controls (positive controls) 
Plasmid controls prepared in section 2.3.5 (Chapter 2) to be used as templates in PCR 
reactions to mimic the naturally occurring mutations of TERC/TERT were used during the 
assay development. Since the assay had to mimic a real sample from a patient, each plasmid 
control (1×10
-4 
ng/μl) had to be diluted into 40ng/μl of a normal genomic DNA (prepared in 
section 2.2.2, Chapter 2) to create a heterozygous mix of a mutant allele and normal WT 
DNA. Mutations of TERC/TERT are usually heterozygous in patients, thus it was imperative 
to ensure that all the samples to be used in the development of the assay are closely similar to 
a real patient sample. All plasmid controls were diluted with WT genomic DNA up to 20% 
allele content within the mix. The principle used to generate heterozygous mixes was that a 
human genomic DNA has two copies of alleles which either of them could harbour a 
mutation of TERC/TERT, while a plasmid has one copy. Both plasmid and human genomic 
DNA has a number of base sequences and the length. This information was used to determine 
a number of plasmid copies required to make a 20% mutation allele with a dilution by a 
normal human genomic DNA to make a heterozygous sample.  
 
Using the information that one human cell yields approximately 10 picomoles of DNA 
indicated that 40ng/μl of human genomic DNA has 8000 alleles. The number of copies of 
plasmid required to make 20% allele mutation and 80% WT genomic DNA were calculated. 
These formulas: [number of copies of plasmid (N) = number of moles (n) × Avogadro’s 
Constant (NA= 6.022045 ×10
23
)], [n = Molecular weight of a double stranded DNA (dsDNA) 
× length of based paired plasmid DNA] were used to determine a relevant concentration of 
plasmid (1×10
-4 
ng/μl) needed to make a 20% allele mix with a dilution by 40ng/μl WT 
genomic DNA. A ratio of plasmid to WT genomic DNA of 1:19 alleles was used to create a 
heterozygous mix. Finally, a heterozygous mix of each mutant and a WT genomic DNA mix 
(1×10
-4
ng/μl: 40ng/μl) was created to be used for assay development. 
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3.2.1.C: Multiple Heterozygous positive controls  
Multiple heterozygous positive controls were prepared to be used as positive controls for the 
finalised assay. To prepare the TERC positive control (TCC), the heterozygous mutant 
positive controls (see section 3.2.1.B) for all four mutants: TERC53C, TERC110C, 
TERC178C and TERC180C were mixed in equal quantities, making a cocktail with each 
mutant allele being present at ±5%. Two TERT multiple positive controls were made, TTC1 
containing TERT412C, TERT704C, TERT846C, TERT1015C and TERT1090C, resulting in a 
mutant allele of ± 4% after addition of equal volumes of 5 heterozygous mixes of plasmid 
positive controls, sitting at ±20%,  and TTC2 comprising of TERT202C and TERT694C, 
making an allele cocktail of each mutant being available of ±10%. Each of these controls 
would be used when the assay is performed.  
 
3.2.1.D: Saliva DNA samples 
Saliva (2ml) was collected using the Oragene
® 
DNA (OG-500) kit (DNA Genotek Inc, 
Canada) from healthy individuals with informed consent (approved by the Faculty of Health 
Sciences Research Ethics Committee, University of Cape Town -HREC REF: 131/2011). The 
saliva sample was then used to extract DNA using the QIAmp
®
 DNA blood mini kit (Qiagen, 
USA). Briefly, 200μl of saliva with Oragene
®
 DNA buffer was mixed with 20μl proteinase K 
(4U/mg) to degrade proteins, 5μl RNAse A (10mg/ml) to degrade RNA and 200μl lysis 
buffer (contained 5% SDS and low pH).  
 
 This was followed by incubation at 56⁰C for 10 minutes to help cell lysis. Subsequently 
200μl of ethanol was added to the sample to dehydrate the DNA (aids in silica binding) 
before loading onto the silica QIAamp
®
 mini spin column, and the sample was passed 
through the column via centrifugation (8000 rpm for 1 minute). The bound DNA was washed 
sequentially with two buffers (AW1 and AW2) to remove impurities (proteins and salts) 
(500μl each buffer, 8000 rpm for 1 minute).   Remaining wash buffer was removed by a final 
centrifugation at 14000 rpm for 1 minute. The DNA was then eluted from the silica column 
by incubation with 50μl nuclease-free water at room temperature for 1 minute followed by 
centrifugation at 8000 rpm for 1 minute.  The concentration of DNA was determined using a 
UV-Vis Spectrophotometer Nano-Drop 2000 (Thermo Scientific, USA) and stored at -20⁰C.   
This DNA sample was used during the validation process.  
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3.2.2 Allele-specific mutant TERC and TERT primers 
Mutant-specific forward primers were designed by ensuring that the 3’ base was specific to 
the mutation (Dieffenbach et al., 1993, Hirotsu et al., 2010, Liu et al. 2012).  This limited the 
placement of the primers, but GC content, primer-dimer formation and hair-pin structures 
were controlled to some extent with the primer length. Common reverse primers were also 
designed and all the primers were checked for primer-dimer formation with one another using 
Primer3 software, ensuring minimal hairpin formation and self-complimentary. Theses 
primers were tested for specificity against the human genome using NCBI blast, to ensure no 
non-specific binding. Table 3.1 lists the primers that were selected for the multiplex 
diagnostic assay for TERC/TERT mutation detection. Primers were also designed to amplify a 
TERC-control region of TERC (using M-TCTRL and M-TCR primers), as well as TERT 
control region in exon 2, TERT-control (using M-TTCTRL and M-TT202R primers). All 
primers were supplied by the Molecular and Cell Biology Department of the University of 
Cape Town.   
 
 
Table 3.1: Primers to detect TERC/TERT mutants in an allele-specific PCR 
 
$
: Forward and reverse primers to amplify TERC mutants and TERC control fragment and TERT mutants.  
Allele-specific primers were named using either their DNA location or amino acid base change while reverse 
primers were named using the same principle. All primers designed specifically for the multiplex their names 
started with a letter M, and for TERC primers with TC after letter M while TERT primers with a TT. Primers for 
internal controls were also named based on either representing TERC or TERT. 
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3.2.3 Allele-specific single-plex PCR of TERC and TERT mutants 
Each primer pair was initially tested in individual single-plex reactions against the specific 
heterogeneous mutant mix as follows: 1X Green GoTaq
®
 Flexi Buffer (Promega, USA), 2U 
GoTaq Hot Start Polymerase (Promega, USA), 0.8mM dNTPs, a range of 0.5mM- 1.5mM 
magnesium chloride (Promega, USA), a range of 3.2pmol- 37.5pmol forward primer and 
25pmol reverse primer (Table 3.1) and either 40ng genomic DNA (negative control) or 
heterozygous positive control (40ng genomic DNA/1 × 10
-4
ng plasmid) or  1 × 10
-4
ng 
plasmid (positive control).   
 
The PCR cycling conditions were as follows: Taq DNA polymerase activation and initial 
template DNA denaturation at 95°C for 4 minutes, followed by a range of 30- 35 cycles of 
template denaturation at 94°C for 30 seconds, primer annealing at a range of 40°C- 65°C for 
30 seconds, and extension at 72°C for 90 seconds.  For amplicon completion, a final 
extension step of 72°C for 8 minutes was added. PCR products were resolved by agarose gel 
electrophoresis, using a 2% TAE-agarose gel and electrophoresis in 1X TAE buffer (40mM 
Tris, 20mM acetic acid, 1mM EDTA) at 70 volts for 1.5 hours. The DNA amplicons were 
stained with ethidium bromide (0.5 μg/ml) (Sigma, USA) and visualized under UV light 
using the UV doc system (UVItec, UK).   
 
3.2.4 Allele-specific multiplex PCR 
3.2.4.A:  Multiplex PCR of TERC mutants  
For the generation of a single-tube amplification system, all four allele-specific forward 
primers, the M-TCTRL forward primer and a common reverse primer (listed in Table 3.1) 
were combined in a single tube (TCMM – TERC master mix).  PCR reactions for detecting 
each mutant in this multiprimer setting were as follows: 1X Green GoTaq
® 
Flexi Buffer 
(Promega, USA), 0.2U GoTaq
® 
Hot Start Polymerase (Promega, USA), 0.8mM dNTPs, 
1.5mM magnesium chloride (Promega, USA), 25pmol forward primer for each TERC allele-
specific forward primer, 3.2 pmol control primer (M-TCTRL) and a common reverse primer 
(M-TCR) and 3% glycerol (in H2O) – plus either 40ng genomic DNA (negative control) or 
heterozygous positive control (40ng genomic DNA/1 ×10
-4
ng plasmid) prepared from section 
3.2.1.B, or multiple heterozygous positive controls prepared from section 3.2.1.C as a 
template. 
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The PCR cycling conditions were as follows: initial denaturation at 95°C for 4 minutes, 
followed by 30 cycles of template denaturation at 94°C for 30 seconds, primer annealing at 
55°C for 30 seconds, and extension at 72°C for 90 seconds, and the addition of a final 
extension step of 72°C for 8 minutes. The PCR amplicons were resolved via agarose gel 
electrophoresis, using a 2% TAE-agarose gel and electrophoresis in 1X TAE (40mM Tris, 
20mM acetic acid, 1mM EDTA) at 70 volts for 1.5 hours.  This was followed by staining 
DNA fragments with ethidium bromide (0.5 μg/ml) (Sigma, USA) and visualized under UV 
light in the UV doc system (UVItec, UK).  
 
3.2.4.B: Multiplex PCR for TERT mutants  
Two different PCR reactions were prepared to detect TERT mutants.  TTMM1 (TERT master 
mix 1) was designed to amplify mutants TERT202 and TERT694, as well as a TERT exon 2 
control fragment. TTMM2 (TERT master mix 2) was designed to amplify mutants TERT412, 
TERT704, TERT846, TERT1015 and TERT1090 from plasmid constructs (Table 2.3, Chapter 
2). The multiplex PCR reactions containing the allele-specific mutant forward primers 
contained the following in a final reaction volume of 25μl: 1X Green GoTaq
® 
Flexi Buffer 
(Promega, USA), 0.2U GoTaq
®
 Hot Start Polymerase (Promega, USA), 0.8mM dNTPs, 
0.5mM magnesium chloride (Promega, USA), 5% DMSO, TTMM1 contained 25pmol M-
TT412, M-TT704, M-TT846, M-TT1015, and M-TT1090 forward primers and 25pmol M-
TT412R, TT-exon5R, M-TT846R, M-TT1015-R and TT-exon14-15R reverse primers, TTMM2 
contained 25pmol M-TT202 and M-TTCTRL, and 75pmol M-TT694 (Table 3.1). The DNA 
template in each reaction was either 40ng WT genomic DNA (negative control) or 40ng 
heterozygous positive control (section 3.2.1.B) or multiple heterozygous positive controls 
prepared from section 3.2.1C as a template. The PCR cycling conditions and product analysis 
were the same as those for TERC (section 3.2.4.A). 
 
3.2.5 Validation of TERC/TERT allele specific multiplex PCR assay 
3.2.5.A: Assay sensitivity   
To determine the ability of the assay to detect low levels of mutant alleles, serial dilutions of 
each plasmid construct (section 2.2.5.D, Chapter 2) into genomic DNA were performed. 
Dilutions were made using the heterozygous mixes made in section 3.2.1.B, which consisted 
of ±20% mutant alleles. Two fold dilutions were prepared in genomic DNA (40ng/μl) to 
produce, ±10%, ±5% and ±2% mutant/WT allele mixtures.  
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These samples, including genomic DNA only were then used as templates in the multiplex 
allele-specific PCR assay described in sections 3.2.4 A and B, using either the TERC 
(TCMM) or relevant TERT master mix (TTMM1 or TTMM2).   
 
3.2.6.B: Assay reproducibility                                                                                                                                                                                                                                                                                                                          
To determine assay reproducibility, the following known samples of heterozygous mixes of 
TERC53C and TERT704C, prepared from section 3.2.1.B, and WT human genomic DNA 
(section 2.2.2, Chapter 2) were used as templates with all three PCR master mixes (TCMM, 
TTMM1, and TTMM2). The PCR reactions were performed as described in sections 3.2.4.A 
and B and the assessment was repeated on three separate occasions. 
 
 3.2.6.C: Assay accuracy assessment 
To determine the accuracy of the assay in identifying mutations, a series of five blinded 
samples (unknowns) was tested using the three master mix reactions (TCMM, TTMM1 and 
TTMM2).  As controls, the combined mutant controls TCC, TTC1 and TTC2 (section 
3.2.1.C) were used as positive controls for the assay being amplified by TCMM, TTMM1 and 
TTMM2 PCR master mixes respectively. The PCR reactions were performed as described in 
sections 3.2.4.A and B. This assessment was repeated in triplicate to ensure the 
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3.3 RESULTS  
 
3.3.1 Experimental design 
Allele-specific primers were designed, such that they were 100% homologous to the mutated 
sequence. This was accomplished by designing primers with a mutated sequence being 
present at the 3’end of each forward primer, making it possible to select and amplify only the 
mutant in a multiplex PCR.  The binding positions of the primers for this multiplex assay 
development were similar to primers used to generate mutants as shown in Figures 2.1, 2.2, 
and 2.3 of Chapter 2.   For the TERC multiplex PCR, as the mutations were all within an 
800bp fragment, it was possible to again use a common reverse primer to allow amplification 
with any of the TERC allele-specific primers.  Therefore the aim was to combine all 4 TERC 
allele-specific mutant forward primers and the common reverse primer (M-TCR). These 
primers are listed in Table 3.1 (section 3.2.2). 
 
  For the multiplex analysis of the TERT mutations, seven allele-specific forward primers 
were designed (see Table 3.1). Due to the large area between mutations, it was necessary to 
create primer pairs for most of the mutations. These primers were M-TT202 and M-TT202R 
for TERT202, M-TT412 and M-TT412R for TERT412, M-TT846 and M-TT846R for 
TERT846, M-TT1015 and M-TT1015R for TERT1015, and M-TT1090 and TT-exon14-15 for 
TERT1090. The only exception was the amplification using the allele-specific forward 
primers for TERT694 and TERT704 in exon 5, which both used the common reverse primer 
TT-exon5R. All primer sequences are listed in Table 3.1.  
 
3.3.2 Single-plex PCR assessment for TERC mutations  
3.3.2.A: Testing of allele-specific primers on the plasmid positive controls 
The first step in the development of the multiplex assay was to confirm the ability of the 
allele-specific primers to amplify the mutant target and to find a common PCR program that 
would be suitable to amplify products using each of the primer sets. The PCR program 
initially used included 40 seconds for annealing, 90 seconds for extension,  and  a  range of 
40- 64⁰C for the annealing temperature for 30 seconds and 35 cycles. The experiments were 
performed as described in section 3.2.3, using 25pmol of the primers and plasmid constructs: 
TERC178C, TERC180C, TERC110C and TERC53C as templates.  
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Using primers M-TC178 and M-TCR to amplify from the plasmid TERC178C yielded a 
single, correct-sized product (445bp) over the 40- 64⁰C range of annealing temperatures.  
Figure 3.1.A shows the amplification of the TERC178 mutant amplicon over this range. 
Primers M-TC180 and M-TCR also produced a single, correctly sized amplicon (450bp) and 
very good amplicon yield across the temperature gradient tested, when using TERC180C as a 
template. Figure 3.1.B shows the amplification of the TERC180 mutant amplicon over the 40- 
64⁰C annealing temperature range. Although not always shown in the figures, a no-template 





Figure 3.1: Electrophoretic analyses of gradient PCR of allele-specific PCR primers for TERC178 and 
TERC180 mutants. 
Allele-specific primers for mutations of TERC were tested using positive control plasmid constructs in single-
plex reactions. The picture above shows the amplicons that were produced when M-TC178 and M-TCR were 
combined (A) and M-TC180 and M-TCR (B) using an annealing temperature gradient from 40°C- 64°C, using 
the plasmid constructs TERC178C and TERC180C respectively, as templates. PCR products were resolved on 
2% agarose TAE gel stained with ethidium bromide and visualized with UV light. Lane MW: Low molecular 
weight ladder (NEB), NC: no-template control.   
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The M-TC53 and M-TCR primer combination (for the amplification of the TERC53 mutation) 
was tested using the TERC53C plasmid construct. Amplification using annealing 
temperatures above 55⁰C produced a specific product of the correct size (554bp) and 
appropriate yield (shown in figure 3.2.A). However, at 55⁰C a fairly negligible non-specific 
product of a slightly smaller size than the correct product was produced, which increased in 
yield as the annealing temperature was reduced below 55⁰C, while the yield of the expected 
product was significantly reduced (see Figure 3.2.B). Amplification with primers M-TC110 
and M-TCR, using TERC110C plasmid construct as a template produced the most specific 
amplification (470bp) at annealing temperatures below 50⁰C, with a smaller non-specific 
amplification band appearing at higher temperatures (Figure 3.2.C).  
 
Due to the problems experienced with these two reactions, an annealing temperature of 55⁰C 
was found to be a suitable compromise to allow specific amplification with all the primer 
sets. The yield of the non-specific product using the TERC110 primers was fairly low 
compared to that of the specific product at 55⁰C and it is likely that using temperatures below 
55⁰C would be problematic when the primers are combined in a multiplex reaction. In 
addition, it is possible that the amplification of those non-specific bands not occur the 








Figure 3.2: Electrophoretic analyses of gradient PCR of allele-specific PCR primers (M-TC53 and M-
TC110). 
Allele-specific primers for mutations of TERC were tested using positive control plasmid constructs in single-
plex reactions. The picture above shows the amplicons that were produced when M-TC53 and M-TCR were 
combined and tested with annealing temperatures of 40°C- 60°C, using TERC53C as a template (A) & (B). 
Panel C shows the amplification using M-TC110 and M-TCR, over the annealing temperature range 40°C- 55°C, 
using TERC110C as a template. PCR products were resolved on a 2% agarose TAE gel stained with ethidium 
bromide and visualized with UV light. Lane MW: Low molecular weight ladder (NEB). 
 
 
3.3.2.B: Testing of allele-specificity using WT human genomic DNA as a template 
In order to ensure that the allele-specific primers were specific for the mutants and not the 
WT human genomic DNA under these PCR cycling conditions, we tested each the primer 
pairs in single-plex reactions using WT genomic DNA as template and as a positive control, 
the plasmid constructs were used as templates. As an amplification control, we also tested a 
control primer set (M-TCTRL and M-TCR) which would amplify a 632bp region of the TERC 
gene regardless of the mutation status of the gene.  
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This control region was named TERC-control. The PCR conditions used were an annealing 
temperature of 55⁰C (as decided above) and 35 cycles, using 25pmol of each primer (Table 
3.1) as described in section 3.2.3.  Figure 3.3 shows the results of this experiment. The PCR 
conditions used were an annealing temperature of 55⁰C (as decided above) and 35 cycles, 
using 25pmol of each primer (Table 3.1) as described in section 3.2.3. The correct sized 
amplicons amplified successfully using the plasmid-based mutants as templates, while no 
amplification was observed using these primer sets with the genomic DNA. The 
amplification control fragment (TERC-control) (632bp) amplified successfully from the 
genomic DNA, showing that this could be used as a control for our experiments under these 
conditions (Figure 3.3). It also showed that in this current experiment the lack of 
amplification from genomic DNA in the allele-specific reactions was not due to poor quality 
DNA. Overall, this experiment showed that the M-TERC primers were specifically 
amplifying their target genes from plasmid constructs only in the presence of a mutation, 




Figure 3.3: Electrophoretic analyses of allele-specificity for TERC mutant-specific PCR primers. 
Allele specific primers for the 4 TERC mutations were tested on both WT human genomic DNA and plasmid 
constructs in single-plex reactions to check the allele-specific amplification. The photograph above shows the 
amplification using each primer set, using either a plasmid construct or genomic DNA as a template (as 
indicated). A: M-TC53 and MTCR, B: M-TC110 and M-TCR, C: M-TC178 and M-TCR, D: M-TC180 and M-
TCR, and E: M-TCTRL and M-TCR. PCR products were resolved on 2% agarose TAE gel stained with ethidium 
bromide and visualized with UV light. Lane MW: low molecular weight ladder (NEB). 
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The correct sized amplicons were amplified very well using the plasmid-based mutants as 
templates, while no amplification was observed using these primer sets with the genomic 
DNA. The amplification control fragment (TERC-control) (632bp) was amplified very well 
from the genomic DNA, showing that this could be used as a control for our experiments 
under these conditions. It also showed that in this current experiment the lack of 
amplification from genomic DNA in the allele-specific reactions was not due to poor quality 
DNA. Overall, this experiment showed that the M-TERC primers were specifically 
amplifying their target genes from plasmid constructs only in the presence of a mutation, 
under these specific PCR conditions. 
 
3.3.3 Multiplex PCR assessment of TERC mutations.  
3.3.3.A: Simultaneous detection of TERC-control and individual mutants. 
 Heterozygous mixes prepared in section 3.2.1.B were used as templates to test the 
simultaneous amplification of each mutant from the plasmid constructs together with the 
control amplicon (TERC-control) from genomic DNA. Each allele-specific forward primer 
was initially combined separately with the control forward primer (M-TCTRL) and the 
common reverse primer (M-TCR) and tested with the relevant heterozygous mix, using this 
PCR reaction setup: 1X Green GoTaq
®
 Flexi Buffer (Promega, USA), 0.2U GoTaq
®
 Hot 
Start Polymerase (Promega, USA), 0.8mM dNTPs, 1.5mM magnesium chloride (Promega, 
USA), 25pmol forward primer for each TERC allele-specific forward primer  (Table 3.1) and 
25pmol common reverse primer (M-TCR). The PCR cycling conditions were performed as 
described in section 3.2.4.A with 35 cycles. While a faint band (Figure 3.4) which 
corresponds to amplification from the TERC180C plasmid was observed, there were no 
visible amplicons from the other positive plasmid controls when using the heterozygous 













Figure 3.4: Electrophoretic analyses of multiplex PCR for TERC-control and each TERC mutant 
amplification.  
Multiplexes containing a specific Allele-specific primer (25pmol), M-TCTRL (25pmol) and M-TCR (25pmol) 
were used to amplify their specific targets using the heterozygous plasmid/genomic DNA as templates. Each 
lane name refers to the specific plasmid present in the heterozygous template mix (TERC180C and TERC 110C 
were done in duplicate) that was used. PCR amplicons were resolved on a 2% agarose TAE gel stained with 
ethidium bromide and visualized with UV light. Lane MW: molecular weight ladder (NEB), and NC: no-
template DNA control.  
 
 
In order to improve the simultaneous amplification of each mutant from their specific 
plasmid in the presence of the control amplicon (TERC-control), the concentration of M-
TCTRL (control forward primer) was reduced in an attempt to reduce the amplification of this 
product. A single-plex PCR reaction series using only the control primer set (M-TCTRL and 
M-TCR), with 40ng WT genomic DNA as a template was performed, where the concentration 
of forward primer M-TCTRL ranged from 25pmol- 2.5pmol and the PCR conditions were 
those described in section 3.2.3,  using 55°C annealing temperature and 35 cycles of PCR. 
Amplification of TERC-control decreased gradually as M-TCTRL concentration was reduced 
as expected (results not shown). The use of 3.1pmol of M-TCTRL for all further experiments 
was decided upon as it showed to allow a reasonable amplification of TERC-control. The use 
of the reduced M-TCTRL (3.1pmol) concentration was then tested with each set of allele-
specific primers, using this PCR reaction conditions setup: 1X Green GoTaq® Flexi Buffer 
(Promega, USA), 0.2U GoTaq
®
 Hot Start Polymerase (Promega, USA), 0.8mM dNTPs, 
1.5mM magnesium chloride (Promega, USA), 25pmol forward primer for each TERC allele-
specific forward primer (Table 3.1) and 25pmol common reverse primer (M-TCR), using 
either each specific heterozygous mix prepared from section 3.2.1.B or a WT genomic DNA 
as a control.  
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The cycling PCR conditions were performed as described in section 3.2.4.A with 35 cycles. 
TERC53 (Figure 3.5.A), and TERC110 (results not shown) were successfully amplified well 
using the corresponding heterozygous mixes as PCR templates, showing clear bands for the 
control amplicon (TERC-control) and amplification of the relevant mutant product. 
Amplification of the TERC178 mutant (Figure3.5.B) from the heterozygous mix was slightly 
less efficient, but of the correct size, while amplification using primer M-TC180 of the 
TERC180 multiplex gave multiple products when using the heterozygous mix 




Figure 3.5: Electrophoretic analyses of multiplex for TERC-control and each TERC mutant amplification 
using 3.1pmol M-TCTRL.  
Multiplexes containing each specific allele-specific primer (25pmol), M-TCTRL (3.1pmol) and M-TCR 
(25pmol) were used to amplify their specific targets using the heterozygous plasmid/genomic DNA or WT 
genomic DNA as templates.   A: primers M-TC53, M-TCR and M-TCTRL  using TERC53C/WT genomic DNA 
mix or WT genomic as a template, B: primers M-TC178, M-TCR, M-TCTRL using TERC178C/WT genomic 
DNA mix or WT genomic DNA, C: primers M-TC180,  M-TCR and M-TCTRL using TERC180C/WT genomic 
DNA mix.  PCR products were resolved on 2% agarose TAE gel stained with ethidium bromide and visualized 
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To further improve the amplification of the TERC178 mutant, its allele-specific primer (M-
TC178) was increased to 37.5pmol while maintaining all other PCR parameters and reagents 
as described above and using a heterozygous mix (TERC178C/WT genomic DNA) prepared 
from section 3.2.1.B. The cycling PCR conditions were performed as described in section 
3.2.4.A with 35 cycles. After increasing this primer concentration, the amplification of 
mutant TERC178 from a heterozygous mix (TERC178C/WT genomic DNA) was greatly 
improved, while still allowing amplification of the control fragment (TERC-control) (as seen 




Figure 3.6: Electrophoretic analyses of multiplex PCR for TERC-control and TERC178 amplification 
with altered primer concentrations.  
The effect of combining the following primers: M-TC178, M-TCTRL and M-TCR in the respective quantities: 
37.5pmol, 3.1pmol and 25pmol, was tested using the TERC178C/WT genomic DNA heterozygous positive 
control and WT genomic DNA as templates (done in duplicate). The PCR products were resolved on 2% 
agarose TAE gel stained with ethidium bromide and visualized under UV light. Lane MW: molecular weight 
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Thus far, by changing the ratios of the various primers, we could achieve the successful dual 
amplification of most of the TERC mutants along with the TERC-control fragment. Several 
different approaches were tested to try to eliminate the non-specific amplification that was 
observed with the M-TC180, M-TCR and M-TCTRL primer combination, which include 
varying the annealing temperature range from 55°C to 60°C to try to improve primer binding 
specificity, adjusting the extension time from 90 seconds to 120 seconds, and decreasing the 
concentration of the M-TC180 allele-specific primer and anticipated that it would minimize 
the non-specific binding of primers. However this did not improve the result either. 
 
However, further optimization revealed that the non-specific bands were only produced the 
plasmid construct TERC180C was used as a template.  If either a purified SDM PCR product 
(TERC180 SDM) or WT genomic DNA was used as a template with these specific primers, 
the non-specific amplification was not observed (results not shown). This showed that the 
problem was caused by sequences present on the plasmid. Since these sequences would not 
be present in the context of the finalised diagnostic assay, we decided to proceed with other 
experiments to develop the multiplex PCR for TERC mutations.   
 
3.3.3.B: Multiplex PCR of all allele-specific primers for TERC mutations  
The 4 allele-specific forward primers: M-TC53 (25pmol), M-TC110 (25pmol), M-TC178 
(37.5pmol),  and M-TC180 (25pmol) for the TERC mutants together with a 3.1pmol for 
control forward primer (M-TCTRL) and 25pmol of the common reverse primer (M-TCR) 
(Table 3.1) were combined into one reaction tube, using this PCR condition: 1X Green 
GoTaq Flexi Buffer (Promega, USA), 0.2U GoTaq
®
 Hot Start Polymerase (Promega, USA), 
0.8mM dNTPs, 1.5mM magnesium chloride (Promega, USA), using each of the 4 
heterozygous mix of individual mutant prepared from section 3.2.1.B as a template. The PCR 
cycling was performed as described in section 3.2.4.A with 35 cycles at 55°C. 
 
Unexpectedly, this primer combination produced at least one non-specific amplicon when 
any of the heterozygous templates were used (data not shown). We postulated that the 
multiple products could potentially be caused by non-specific binding of unrelated primers to 
newly synthesized product that occur later on in the cycling process. To test this theory and 
improve the specificity, the number of PCR cycles was reduced to a range of 25 and 30 
cycles to determine a suitable cycling condition using PCR conditions as described above.  
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Figure 3.7 shows the effect of reducing the number of cycles on the amplification of TERC53 
and TERC110. As can be seen, reducing the number of cycles to 30 cycles improved the 
specificity of the amplification, producing only the expected TERC53 and TERC-control 
amplicons (Lane 1) when using the TERC53C/WT genomic DNA heterozygous mix. 
However, the alteration of this parameter did not improve the non-specific amplification 
observed when using the TERC110C/WT genomic DNA heterozygous mix (Lane 2). In the 
case of TERC178 and TERC180, the desired products were amplified, with no non-specific 
bands, when TERC178C and TERC180C heterogeneous mixes were used, using 30 cycles of 




Figure 3.7:  Electrophoretic analyses for the effect of reduced PCR cycle number on non-specific 
amplification using multi-primer master mix.  
The amplification of TERC mutants and the control (TERC-control) was performed using a range of PCR cycles 
to try and eliminate the non-specific product.  The picture above shows the amplification of TERC mutants and 
TERC-control using TERC53C or TERC110C heterozygous mixes and WT genomic DNA as templates, as 
indicated on the figure. Multiplex PCR analysis of TERC53 and TERC110 and TERC-control amplified using 
the multiple primers set:  M-TC53 (25pmol), M-TC110 (25pmol), M-TC178 (37.5pmol), M-TC180 (25pmol), M-
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Since the amplification of TERC110 displayed a non-specific amplicon despite reducing the 
cycles, further optimization was necessary. To this end, the use of various additives was 
tested in the PCR reaction. These additives were tested individually on the multiplex PCR 
and included 0.8μg/μl BSA (0.3μl of 66.6μg/μl BSA in 25μl reaction), 5% DMSO (0.8μl of 
100% DMSO in 25μl reaction) and 3% glycerol (0.75μl of 100% glycerol in 25μl reaction). 
Markoulatos et al. (2002) suggested that using these additives may improve the PCR 
efficiency and reduce non-specific product amplification in a multiplex PCR setting.  
 
These additives were added separately to the multiplex master mix containing all the primers: 
M-TC53 (25pmol), M-TC110 (25pmol), M-TC178 (37.5pmol), and M-TC180 (25pmol) for 
the TERC mutants together with a 3.1pmol for control forward primer (M-TCTRL) and 
25pmol of the common reverse primer (M-TCR) and were tested using each of the 
heterozygous mixes as templates (prepared from section 3.2.1.B). The PCR reaction 
conditions used were: 1X Green GoTaq
®
 Flexi Buffer (Promega, USA), 0.2U GoTaq
®
 Hot 
Start Polymerase (Promega, USA), 0.8mM dNTPs, 1.5mM magnesium chloride (Promega, 
USA).  The PCR cycling was performed as described in section 3.2.4.A with 30 cycles at 
55°C annealing temperature.  
 
The addition of DMSO or BSA did not improve the specificity of amplification of the 
TERC110 mutant (data not shown). On the other hand, the addition of 3% glycerol improved 
the specificity, eliminating the non-specific band. This is illustrated in Figure 3.8 below, 
which shows the amplification of the control TERC fragment (TERC-control) in all of the 
reactions, as well as the amplification of each relevant mutant corresponding to the multiplex 








Figure 3.8: Electrophoretic analyses of TERC multiplex using 3% glycerol in PCR master mix. 
All TERC allele-specific forward primers were combined with M-TCTRL and M-TCR, in a master mix 
containing 3% glycerol. This master mix was then tested with the specific heterozygous mutant positive controls 
or genomic DNA as templates (as indicated on the figure). PCR conditions included 55°C annealing 
temperature, 30 cycles, 25pmol of all primers (M-TC53, M-TC110, M-TC180 and M-TCR (25pmol) of TERC 
mutants except 3.1mol of M-TCTRL and 37.5pmol of M-TC178. The PCR amplicons were resolved on a 2% 
agarose TAE gel stained with ethidium bromide and visualized under UV light. Lane MW: molecular weight 
ladder (NEB), NC: no-template control.    
 
 
3.3.3.C:  TERC Assay positive control (TCC)  
Heterogeneous mixes of TERC, containing all the plasmid constructs and genomic DNA, 
were combined together to be used as a multiple mutant positive control for the assay (TCC). 
While the amplification of the control fragment (TERC-control) serves as an internal control 
for the quality of the genomic DNA used in the assay, a second positive control is needed to 
ensure that each prepared master mix, containing the multitude of primers is capable of 
detecting each mutant in every experiment. Failure of either of these controls would render 
the patient result invalid. 
 
 This positive mutant control mix was tested as a template using the master mix described in 
section 3.2.4.A, with the 3% glycerol added using 25pmol of all primers except 37.5pmol for 
M-TERC178 of TERC178 mutant and 3.1pmol for M-TCTRL of the control fragment (TERC-
control), using 30 cycles of PCR. As can be seen in Figure 3.9, the positive control produced 
TERC53 mutant, TERC110, TERC178, TERC180 and TERC-control bands, as expected 
(Figure 3.9, Lanes 1 and 2), showing that even combinations of mutations could be detected 
simultaneously using this methodology (not expected to occur in a patient though).  
 
  MSc Medicine: Haematology 
75 
 
However, because TERC53 and TERC110 mutants are very similar in size, they were 
resolved as one band. The TERC178 and TERC180 mutant bands were also resolved as one 
band because of the same reason, but the intensity of both mutants is lower than what is 
desirable and further optimization would be required, but due to time constraints, we 
anticipated that further experiments would improve it. Lanes 4 – 7 represent amplification 
using the individual heterozygous mixes as templates and all four produced the expected size 




Figure 3.9: Electrophoretic analyse of TERC multiplex PCR with controls. 
All TERC allele-specific forward primers: M-TC53, M-TC110 M-TC180 and M-TC178 were combined with M-
TCR and M-TCTRL, in a master mix containing 3% glycerol. This master mix was then tested with the specific 
heterozygous mutant positive controls, genomic DNA or combined mutant positive control TCC as templates 
(as indicated on the figure, done in duplicate). PCR conditions included 55°C annealing temperature, 30 cycles, 
25pmol of all primers except 3.1mol of M-TCTRL and 37.5 pmol of M-TC178. The PCR amplicons were 
resolved on a 2% agarose TAE gel stained with ethidium bromide and visualized under UV light. Lane MW: 
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Therefore, the development of the multiplex PCR to detect 4 TERC mutations TERC53, 
TERC110, TERC178 and TERC180 using a single master mix was achieved. A total of 5 
forward primers and a common reverse primer was used to detect either a control fragment 
(TERC-control) alone or a mutant amplicon and control fragment combination. The final 
PCR cycling conditions and reaction set-up for the multiplex were a common annealing 
temperature of 55°C for primers, 30 cycles for PCR cycling, 25pmol of all primers except 
37.5pmol of M-TERC178 and 3.1pmol of M-TCTRL and the addition of 3% glycerol 
(forming the TERC master mix - TCMM). The controls that were used for the assay included 
a mutant negative WT genomic DNA, a no template control (NC) and a combined mutant 
positive control (TCC).  
 
3.3.4 Single-plex assessment for TERT mutations  
3.3.4.A: Testing of allele-specific primers on the plasmid positive controls and WT genomic 
DNA  
In order to develop a single platform assay to test for mutations in both TERC and TERT 
genes, it was important that the PCR cycling conditions that were used for the TERC 
multiplex assay should also be used for the development of the TERT multiplex. As with the 
development of the TERC multiplex, it was necessary to first test the ability of the multiplex 
allele-specific primers of TERT to bind only to their target mutants and not the WT genomic 
DNA sequence. The amplification was performed as described in section 3.2.3 using the 
TERC PCR cycling conditions described above. The multiplex primers were tested in single-
plex reactions, using either the corresponding plasmid positive controls or WT genomic DNA 
as templates. All primers were tested at 25pmol and the relevant primer sequences are listed 
in Table 3.1.   
 
The primer set M-TT412 and M-TT412R, successfully amplified the 180bp product from the 
TERT412C plasmid construct, the M-TT846 and M-TT846R primer set amplified the expected 
240bp amplicon from the TERT846C plasmid construct, and the primer pair M-TT1015 and 
M-TT1015R amplified a 393bp amplicon from the plasmid construct  TERT1015C as 
expected. The correct amplicon was also achieved for the other primer pairs with their 
corresponding plasmid positive controls:  M-TT1090 and MTT-exon14-15R yielding a 
product size of 211bp, M-TT694 and TT-exon5R producing a product sized 353bp.  
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The amplification from TERT704C using M-TT704 and TT-exon5R resulted in the correct-
sized amplicon (323bp), as well as some additional amplicons. Unfortunately, when these 
primer sets were tested using WT genomic DNA as a template, under the TERC cycling 
conditions, amplification of similar sized products was observed for some of the primer sets, 
while others gave multiple amplicons (Figure 3.10.B). This result indicated that under these 




Figure 3.10:  Electrophoretic analysis of PCR to test specificity of TERT allele-specific forward primers.  
Allele-specific primers for mutations of TERT were tested using positive control plasmid constructs or WT 
genomic DNA in single-plex PCR reactions. The picture above shows the use of each primer set to test the 
ability and specificity to amplify their targets from plasmid constructs in Panel A or WT genomic DNA in panel 
B. Lanes 1: primer set M-TT412 and M-TT412R, 2: M-TT694 and TT-exon5R, 3: M-TT704 and TT-exon5R, 4: 
M-TT846 and M-TT846R, 5: M-TT1015 and M-TT1015R, 6: M-TT1090 and TT-exon14-15R. PCR products 
were resolved on 2% agarose TAE gel stained with ethidium bromide and visualized with UV light. Lane MW: 
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Figure 3.10.A shows that the primer set M-TT412 and M-TT412R (Lane 1), successfully 
amplified the 180bp product from the TERT412C plasmid construct, the M-TT694 and TT-
exon5R (Lane 2) produced a product sized 353bp from TERT694C, the primer set M-TT704 
and TT-exon5R (Lane 3) produced a correct-sized amplicon (323bp) from TERT704C, as well 
as some additional non-specific amplicons, the M-TT846 and M-TT846R primer set (Lane 4) 
amplified the expected 240bp amplicon from the TERT846C plasmid construct, the primer 
pair M-TT1015 and M-TT1015R (Lane 5) amplified a 393bp amplicon from the plasmid 
construct TERT1015C as expected, and a correct amplicon was also achieved for the other 
primer pair with its corresponding plasmid positive controls: M-TT1090 and TT-exon14-15R 
(Lane 6) yielding a product size of 211bp from TERT1090C plasmid construct. 
 
 Unfortunately, when these primer sets were tested using WT genomic DNA as a template, 
under the TERC cycling conditions, amplification of similar sized products was observed for 
some of the primer sets, while others gave multiple amplicons (Figure 3.10.B).  This result 




3.3.4.B: Allele-specific primer specificity optimization  
A study by Markoulatos et al (2002) showed that reducing the magnesium chloride prevents 
non-specific binding of primers thus enhancing the specific amplification. Therefore, the first 
step of optimization was to improve the specificity of the primers by varying the magnesium 
chloride concentrations at 1.5mM, 1mM, 0.8mM, and 0.5mM. The PCR reactions were 
performed as described in section 3.2.3, with various magnesium chloride concentrations, 
using the PCR program described in section 3.2.3 with 55°C annealing temperature and 30 
cycles. Individual primer sets of TERT mutants were tested separately using either a WT 
genomic DNA or a plasmid mutant construct. Reducing the magnesium chloride to 0.5mM 
improved the specific amplification, allowing the allele-specific forward primers to only bind 
to their mutated target sequence and amplify from the plasmid controls only, with no 









Figure 3.11:  Electrophoretic analysis of TERT allele-specific primers using 0.5mM magnesium chloride.  
Allele-specific primers for mutations of TERT were tested using positive control plasmid constructs or WT 
genomic DNA in single-plex PCR reactions, using 0.5mM magnesium chloride in the PCR reaction mix. The 
picture above shows the amplification results using the following primers set, A: primer set M-TT694 and TT-
exon5R, B: M-TT846 and M-TT846R, C: M-TT1015 and M-TT1015R, D: M-TT1090 and TT-exon14-15R, E: M-
TT704 and TT-exon5R, F: M-TT412 and M-TT412R. PCR products were resolved on 2% agarose TAE gel 
stained with ethidium bromide and visualized with UV light. Lane MW: Low molecular weight ladder (NEB), 
lane NC: non-template control. 
 
 
3.3.5 Multiplex PCR assessment of TERC mutations  
3.3.5.A: Combination of primer pairs for TERT gene : phase 1 
Due to the large number of primers that were needed to amplify all of the TERT mutants, the 
primers were combined into two sets. The primers M-TT412, M-TT412R, M-TT846, M-
TT846R, M-TT1015, M-TT1015R, M-TT1090 and MTT-exon14-15R were used in the first 
primer set to amplify mutants: TERT412, TERT846, TERT1015, and TERT1090, and the 
primers M-TT694, M-TT704, TT-exon5R, M-TT846 and M-TT846R were used in the second 
set to amplify mutants TERT694, TERT704, and TERT846. The templates that were used in 
this analysis were the heterogeneous plasmid/genomic mixes and WT genomic DNA. The 
PCR cycling was performed as described in section 3.2.4.2, using 25 pmol of each primer and 
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The primer set 1 reaction mix successfully resulted in the amplification of the correct 
amplicons for mutant TERT412 (180bp), TERT846 (240bp), TERT1015 (393bp) and 
TERT1090 (211bp), when the corresponding heterozygous mixes were used as templates, 
while no amplification was observed using WT genomic DNA as a template (Figure 3.12.A). 
However, in the second primer set only TERT846 was successfully amplified. The use of 
TERT694C and TERT704C as templates resulted only in the production of significant 




Figure 3.12: Electrophoretic analysis of multi-primer for TERT PCR: primer sets 1 and 2.  
Primers of TERT were combined into primer sets 1 and  2 and used to amplify their sequence targets using either 
the relevant heterozygous plasmid mixes or WT genomic DNA as templates (as indicated on the figure) Panel 
A: Amplification using primer set 1:  M-TT412 and M-TT412R, M-TT846 and M-TT846R, M-TT1015 and M-
TT1015R, M-TT1090 and MTT-exon14-15R. Panel B: Amplification using primer set 2: M-TT694 and TT-
exon5R, M-TT704 and TT-exon5R, M-TT846 and M-TT846R. The picture above shows the amplicons resolved 
on 2% agarose TAE gel stained with ethidium bromide and visualized under UV light. Lane MW: molecular 
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Due to the lack of PCR product in TERT694 and TERT704, we attempted various approaches 
to improve the amplification of these mutants. Firstly, we increased the concentration of each 
allele-specific forward primer (M-TT694 and M-TT704) from a range 25 pmol to 75pmol in 
order to increase primer binding. The effect of increasing the amount of Taq DNA 
polymerase from 2U to 4Uwas also investigated in order to maximize the DNA synthesis 
during cycling.  In addition, 5% DMSO was also added into the reaction containing 25pmol 
primers/ 2U Taq polymerase to try to decrease the melting temperature of primers and 
improve their binding affinity, a method that was previously described by Henegariu et al 
(1997).  
 
The increase of the forward primer concentration or DNA polymerase or the addition of 
DMSO, all yielded large amounts of amplicon with no obvious increase in yield compared to 
one another (Figure 3.13). For the amplification of TERT694, an increase in the concentration 
of primer M-TT694 increased the yield, as did the addition of DMSO to the master mix. It 
was therefore decided that both of these changes should be made to aid in the amplification of 




Figure 3.13: Electrophoretic analysis for the effect of increased primer, enzyme and DMSO on the 
amplification of TERT694 and TERT704 using primer set 2.   
Primer set 2 containing: M-TT694, TT-exon5R, M-TT704, TT-exon5R, M-TT846 and M-TT846R was used to 
amplify TERT694  and TERT704 mutants using heterogeneous mixes as templates, using either an increased 
amount of Taq DNA polymerase (4U) (A), increased forward primer (M-TT694/M-TT704) (75pmol) (B) or the 
addition of 5% DMSO to the reaction mix (C). The photograph above shows the amplicons of TERT694 and 
TERT704 resolved on 2% agarose TAE gel stained with ethidium bromide and visualized with UV light. Lane 
MW: molecular weight ladder (NEB). 
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Compared to the result observed in Figure 3.12, simply keeping all reagents on ice improved 
the amplification of the TERT704 mutant using the corresponding heterogeneous mix as 
template, with no primer-dimer formation observed. Increasing the forward primer 
concentration or DNA polymerase or the addition of DMSO, all yielded large amounts of 
amplicon with no obvious increase in yield compared to one another (Figure 3.13). For the 
amplification of TERT694, an increase in the concentration of primer M-TT694 increased the 
yield, as did the addition of DMSO to the master mix. It was therefore decided that both of 
these changes should be combined in the amplification reaction to aid in the amplification of 
the TERC694 mutant. 
 
3.3.5.B:  Combination of primer pairs for TERT gene: phase 2 
Once the problem associated with the inefficient amplification of TERT694 and TERT704 
was solved, the next phase of the assay development was started. This involved the 
combination of the following primers:  M-TT412, M-TT694, M-TT704, M-TT846, M-TT1015, 
M-TT1090 forward primers, and M-TT412R, TT-exon5R, M-TT846R, M-TT1015R, and M-
TT-exon14-15R reverse primers into one  PCR master mix to amplify the following mutants: 
TERT412, TERT694, TERT704, TERT846, TERT1015 and TERT1090. The TERC PCR 
conditions were used, with a reaction master mix containing 0.5mM magnesium chloride, 
25pmol for all primers except 75pmol for primer M-TT694 and the addition of 5% DMSO, as 
well as setting up of the reaction on ice as described in section 3.2.4.B, using cycling 
conditions of TERC multiplex as described in section 3.2.4.A.  
 
These reaction conditions were tested using each heterogeneous mix and WT genomic DNA 
as templates. The results of this experiment are shown in Figure 3.14, which shows an 
overwhelming amplification of a primer-dimer product (+/-70bp) when any of the templates 
were used with this multiple primer reaction mix. Despite this, mutants TERT412, TERT846 
and TERT1090 were amplified to some extent using the corresponding heterogeneous mixes 










Figure 3.14:  Electrophoretic analysis of multi-primer TERT analysis: amplification of TERT mutants in 
the presence of 6 allele-specific forward primers. 
 Primers: M-TT412, M-TT694(75pmol), M-TT704, M-TT846, M-TT1015, M-TT1090, M-TT412R, TT-exon5R, 
M-TT846R, M-TT1015R, and M-TT-exon14-15R were combined and used to amplify their respective targets 
from the heterogeneous plasmid mixes as indicated on the figure (in the presence of 5% DMSO). All primers 
were 25pmol except M-TT694 as indicated above. The picture above shows the amplicons resolved on 2% 
agarose TAE gel stained with ethidium bromide and visualized with UV light. Lane MW: low molecular weight 
ladder (NEB), lane NC: no-template control.  
 
 
In order identify the primer set that caused the primer-dimer formation, each set of primers 
was introduced separately into the reaction mix and tested against the heterogeneous mixes. 
The M-TT694 was found to be the main cause of the primer dimer product formation when 
added to the other primers (results not shown). When M-TT694 was excluded from the 
reaction mix, the remaining primers successfully amplified the TERT412, TERT704, 
TERT846, TERT1015, and TERT1090 mutants using the corresponding positive heterozygous 
mixes and showed the lack of amplification of any product when WT genomic DNA was 








Figure 3.15: Electrophoretic analysis of multi-primer TERT analysis: amplification of TERT mutants in 
the presence of 5 allele-specific forward primers (excluding M-TT694).  
 Primers M-TT412, M-TT704, M-TT846, M-TT1015, M-TT1090, M-TT412R, TT-exon5R, M-TT846R, M-
TT1015R, and M-TT-exon14-15R were combined and used to amplify their respective targets from the 
heterozygous plasmid mixes or WT genomic DNA as indicated on the figure (in the presence of 5% DMSO). 
The picture above shows the amplicons resolved on 2% agarose TAE gel stained with ethidium bromide and 
visualized with UV light. Lane MW: low molecular weight ladder (NEB), lane NC: no-template control.  
 
 
3.3.5.C: Optimization of TERT202 and TERT694 detection 
Mutant TERT202 was excluded from the multiplex PCR experiments performed above 
because its original forward primer (5’ CTGGGATGCGAACGGTA 3’) was designed to 
amplify an 812bp fragment using a common reverse primer (M-TT412R) from exon 2. The 
common reverse primer for both TERT202 and TERT412 was used to reduce the number of 
primers to be used in one master mix when the primers are combined in the multiplex. The 
amplification of the TERT202 fragment was achieved using this primer on the plasmid 
mutant TERT202C, using 0.5mM magnesium chloride, 25pmol of primers, 55⁰C annealing 
temperature and 30 PCR cycles as described in section 3.2.3. The PCR cycling conditions 
were found not to be effective for the amplification of such a large fragment. Thus to rectify 
this, we designed another reverse primer (M-TT202R) (Table 3.1) so that a smaller fragment 
could be amplified, which would amplify a 233bp fragment if the mutation was present.  
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This primer was integrated into a TERT master mix containing primers to amplify these 
mutants: TERT412, TERT704, TERT846, TERT1015, and TERT1090. The TERT202 from the 
TERT202C/genomic mix and TERT846 or TERT1090 from their respective positive control 
plasmid/genomic mixes were successfully amplified. However, there was no amplification 





Figure 3.16: Electrophoretic analysis for the incorporation of TERT202 specific primer pair into multi-
primer assay. 
Primers M-TT202, M-TT202R M-TT412, M-TT412R, M-TT704, TT-exon5R, M-TT846, M-TT846R, M-TT1015 
and M-TT1015R  were combined (in the presence of 5% DMSO) and tested against their respective 
heterogeneous plasmid templates or WT genomic DNA (as indicated on the figure). The picture above shows 
the resulting amplicons resolved on 2% agarose TAE gel stained with ethidium bromide and visualized with UV 
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Due to the failure of the forward primer (M-TT694) used to amplify TERT694 from plasmid 
construct TERT694C when incorporated with other allele-specific primers in a multiplex 
PCR, two separate reaction mixes were prepared to amplify the TERT mutations. The first  
PCR reaction mix consisted of 10 primers: M-TT412, M-TT704, M-TT846, M-TT1015, M-
TT1090, M-TT412R, TT-exon5R, M-TT846R, M-TT1015R, and M-TT-exon14-15R to amplify 
mutants: TERT412, TERT704, TERT846, TERT1015 and TERT1090 in one PCR tube and this 
was referred to as  TERT master mix one or TTMM1. The second PCR reaction mix 
contained 4 primers: M-TT202, M-TT202R, M-TT694 and TT-exon5R to amplify mutants 
TERT202 and TERT694 was named TERT master mix two or TTMM2.  
 
The PCR reactions and cycling conditions described in section 3.2.4.B were used: using 
25pmol of all primers, except M-TT694 (75pmol), 5% DMSO in each master mix, 0.5mM 
magnesium chloride in both to maintain the primer specificity and reactions setup on ice. All 
five mutants were amplified successfully, producing single amplicons of the expected size: 
TERT412 (180bp), TERT704 (323bp), TERT846 (240bp), TERT1015 (393bp) and TERT1090 
(211bp), with no primer dimerization and no amplification when only WT genomic DNA was 
used. The mutant products TERT694 (353bp) and TERT202 (233bp) were also successfully 
amplified a PCR product of the correct band sizes using TTMM2. Therefore use of two 
master mixes thus allowed the successful specific amplification of 7 TERT mutations (Figure 
3.17). 
  




Figure 3.17:  Electrophoretic analysis of multi-primer combinations TTMM1 and TTMM2 used to 
amplify their respective TERT mutations. 
Two primer master mixes (TTMM1 and TTMM2) were used to amplify each mutant of TERT using either 
heterogeneous mixes or WT genomic DNA as templates (as indicated on the figures). Panel A: Amplification 
using TTMM1, which contained: M-TT412, M-TT412R, M-TT704, TT-exon5R, M-TT846, M-TT846R, M-
TT1015, M-TT1015R, M-TT1090 and M-TT-exon14-15R. Panel B: Amplification using TTMM2, which 
contained: M-TT202, M-TT202R, M-TT964 and TT-exon5R.perfomed in duplicate. The picture above shows the 
amplicons resolved on 2% agarose TAE gel stained with ethidium bromide and visualized under UV light. Lane 
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3.3.6 Control amplicon for TERT mutation detection assay 
The design of our assay was such that the allele-specific primers would only bind if the 
mutations were present and thus an amplification product would only be produced in the 
presence of a mutation. In case of genomic DNA being tested that does not contain mutations 
(WT genomic DNA) and therefore there would be no amplicons produced. Unfortunately, the 
lack of an amplicon could also be due to PCR failure and thus lead to false negative results. 
Failure of PCR amplification could be due to different reasons, such as the lack of DNA 
added as template in the PCR reaction, poor quality DNA, a reagent missing from the master 
mix and also failure of the PCR machine itself. Therefore, it is very important to be able to 
avoid these false results. This is achieved by allowing the amplification of a control product 
simultaneously with the amplicon of interest. This control amplification has to be amplified 
in the presence or absence of the mutation to ensure that the PCR reaction conditions were 
favorable.  
 
Due to two master mixes being used for the amplification of the TERT mutations (TTMM1 
and TTMM2), two controls were required. For the TTMM1 mix, the first control forward 
primer to be tested was designed to exon 2 to yield an amplicon of 900bp. A single-plex PCR 
was attempted using 25 pmol of this forward primer: 5’CAACACGGTGA CCGACGCA 3’ 
with  reverse primer M-TT412R (Table 3.1) using the PCR conditions described in section 
3.2.4.2, which included the  0.5mM magnesium chloride, 40ng WT human genomic DNA as 
a template. This PCR yielded no amplification (results not shown). In order to improve the 
amplification of the control fragment, the single-plex PCR was performed using different 
concentrations of control primer ranging from 50pmol, 75pmol and 100pmol, and WT human 
genomic DNA as a template.  
 
This control amplicon was successfully amplified at 75 pmol and 100 pmol control primer 
concentration (results not shown). This control forward primer (100pmol) was then added to 
the TTMM1 reaction mix and tested using either a WT genomic DNA or heterogeneous 
mixes of TERT412C and TERT704C as templates. While the amplification of the mutants was 
successful in the presence of this additional primer, there was no co-amplification of the 
control fragment. This was also the case when only genomic DNA was used as a template 
(Figure 3.18.A). The successful amplification using these primers alone indicated that the 
DNA quality was not preventing amplification (Figure 3.18.B).  
 




Figure 3.18: Electrophoretic analysis of multi-primer combination (TTMM1) used to amplify TERT412 
and TERT704 separately with control amplification and single-plex PCR for control only.   
Multi-primer combination (TTMM1) was used to amplify either TERT412 and TERT704 with control 
amplification using heterogeneous mixes (as indicated on the figure) or WT genomic DNA as templates (as 
indicated on the figures). Single-plex PCR was used to amplify the control amplification using WT genomic 
DNA as a template. A: Amplification using TTMM1, which contained: M-TT412, M-TT412R, M-TT704, TT-
exon5R, M-TT846, M-TT846R, M-TT1015, M-TT1015R, M-TT1090 and M-TT-exon14-15R and control 
amplification primer. B: Amplification using single-plex PCR which contained: control primer and M-
TT412R. The picture above shows the amplicons resolved on 2% agarose TAE gel stained with ethidium 




Due to the lack of amplification when the control primer was combined in TTMM1, we 
designed an additional 3 forward primers from exon 5, 5’ CAACACACATGCGGCCAG 3’ 
(for TERT exon 5 control 1), 5’ TGCGGTGGCTGCGGTGA 3’ (for TERT exon 5 control 2), 
and 5’ CCCCGTCATC TGAGGAGAG 3’ (for TERT exon 5 control 3), which would use a 
reverse primer (TT-exon5-R) (for exon 5 primers), from their corresponding exons to produce 
amplicons. These were designed to amplify control fragments in the region of exon 5 for 
TERT (between 15541bp-16021bp). These primers were  tested in single-plex PCRs using 
either 0.5mM or 1.5mM magnesium chloride in separate master mixes, 25 pmol of each 
primer, 40 ng WT human genomic DNA as template, 55ºC annealing temperature, and 30 
PCR cycles.  
  MSc Medicine: Haematology 
90 
 
There was no amplification in the reaction master mix with 0.5mM MgCl2, but from a master 
mix with 1.5mM MgCl2, there was a good amplification when these primers were used 
(Figure 3.19).  This indicated that these primers would not be suitable to work either in the 
TTMM1 or TTMM2 master mixes. As a result, these primers were excluded from the master 




Figure 3.19 Effect of MgCl2 concentrations on the amplification from prospective TERT control amplicon 
primers (exon 5).  
Single-plex PCRs were performed using control primers of TERT either in a PCR reaction mix with 0.5mM 
MgCl2 or 1.5mM MgCl2 using WT genomic DNA as a template. Lane MW: 1kb molecular weight ladder 
(NEB), lane NC: no template control (0.5mM magnesium chloride). Panel of 0.5mM magnesium chloride: lane 
1: TERT exon 5 control 1primer, lane 2: TERT exon 5 control 2 primer, lane 3 and 4: TERT exons 5 control 3 
primer. Panel of 1.5mM magnesium chloride: lane 5: TERT exon 5 control 1 primer, lane 6: TERT exon 5 
control 2 primer, lane 7 and 8: TERT exon 5 control 3 primer. All forward primers were combined with the M-
TTexon5R primer. The amplicons were resolved on 2% agarose TAE gel stained with ethidium bromide and 
visualized under UV light.  For the amplification of a control amplicon using the TTMM2 mix, 
we designed a forward primer (M-TTCTRL) (Table 3.1) from exon 2 of TERT which would 
amplify a 450bp amplicon when combined with reverse primer M-TT202R. This primer pair 
was tested in a single-plex PCR using 25pmol of each primer, 0.5mM magnesium chloride, 
5% DMSO, 40ng WT human genomic DNA, 55ºC annealing temperature, and 30 PCR 




  MSc Medicine: Haematology 
91 
 
Figure 3.20 shows the result on the amplification of mutants TERT202 and TERT694 and the 
control amplicon when M-TTCTRL was combined with the other primers in TTMM2, using 
heterozygous mixes of TERT202C and TERT694C or WT genomic DNA as templates. The 
amplification of the mutant products was not inhibited by the addition of this extra primer. 
The control amplicon was successfully amplified off WT genomic DNA as well as the 
TERT694C heterozygous mix. However, amplification of the control amplicon was not 
observed when the TERT202 mutant amplicon was amplified. This is probably due to the 
preferential amplification of the smaller product, in light of the fact that both reactions are 





Figure 3.20:  Incorporation of M-TTCTRL into TTMM2 to allow for the TERT control fragment 
amplification. 
The TERT202 and TERT694 mutants were individually amplified simultaneously with the control amplicon 
(TERT-control) from heterozygous mixes using a master mix containing 5% DMSO and the following primers: 
M-TERT202, M-TERT202R, M-TERT694, TT-exon5-R, M-TTCTRL and M-TERT202R. The PCR amplicons 
were resolved on 2% agarose TAE gel stained with ethidium bromide and visualized under UV light. Lane MW: 
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As indicated above, each master mix was intended to have a positive control which would be 
amplified simultaneously with the amplicon of interest. For the TERC TCMM mix (section 
3.3.3.A) and TTMM2 of TERT, the positive control primers were incorporated successfully 
into the reactions. Unfortunately for TTMM1, none of the designed primers worked in the 
multi-primer environment (11 primers). As all 3 master mixes would be performed at the 
same time, we felt that 2 control amplicons were enough to carry on with the assay and would 
be used to account for issues of poor quality DNA, poor quality reagents or failure of the 
PCR machine itself.   
 
3.3.7 TERT assay positive controls (TTC1 and TTC2)  
Heterozygous mixes of TERT, containing 5 plasmid constructs (TERT412C, TERT704C, 
TERT846C, TERT1015C, and TERT1090C) and WT genomic DNA in one tube, and another 
one consisting of 2 mutants (TERT202C and TERT694C) and WT genomic DNA in another 
tube were prepared to be used as multiple mutant positive control for the assay (TTC1 and 
TTC2). As indicated in TERC assay, although the amplification of the control fragment 
(TERT-control) works as an internal control for the quality of the genomic DNA used in the 
assay, a second positive control is necessary to confirm that each master mix used consists of 
multiple primers that are able to detect each mutant in every experiment. These positive 
mutant control mixes were tested as templates using the master mixes described in section 
3.2.4.A, with the 5% DMSO added using 25 pmol of all primers except 50pmol for M-
TERT694 of TERT694 mutant using 30 cycles of PCR.  
 
The amplification of the positive controls with only TERT1090 and TERT704 mutants was 
successful, while the amplification of the other 3 mutants (TERT412, TERT846 and 
TERT1015) from the TTMM1 master mix was not successful (Figure 3. 21). In the second 
positive control of TERT, all mutants were amplified, together with the TERT-control 
fragment, showing that the multiple templates were working accordingly from the master mix 
TTMM2 (Figure 3.21). As only two mutants were amplified in the first positive control of 
TERT, we felt that there were enough to be positive controls since in this assay we are only 
interested to detect if the patient would have a mutation or not. Since in the literature, either 
one of TERT mutations has been reported, there is no case where the patient would carry 
more than one of these mutations.  
  MSc Medicine: Haematology 
93 
 
It was considered that the amplification of only two mutants sufficient to conclude the assay 
to be used as it has been shown that all mutants are amplified when only one mutant/genomic 




Figure 3.21: Electrophoretic analyse of TERT multiplex PCR with controls. 
Allele-specific forward primers: M-TT412, M-TT412R, M-TT704, TT-exon5R, M-TT846, M-TT846R, M-
TT1015, M-TT1015R, M-TT1090 and M-TT-exon14-15R were combined in the TTMM1 master mix and other 
allele-specific primers: M-TT202, M-TT202R, M-TT964 and TT-exon5R were combined with M-TTCTRL in the 
TTMM2 master mix, both master mixes contained 5% DMSO. TTMM1 master mix was tested with a combined 
mutant control TTC1 or specific heterogeneous mutant positive controls, while TTMM2 master mix was tested 
with a combined mutant positive control TTC2 as templates (as indicated on the figure). PCR conditions were 
55°C annealing temperature, 30 cycles, 25pmol of all primers except 50pmol of M-TERT694. The PCR 
amplicons were resolved on 2% agarose TAE gel stained with ethidium bromide and visualized under UV light. 
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The development of the multiplex PCR to detect 5 TERT mutations: TERT412, TERT704, 
TERT846, TERT1015 and TERT1090 using a single master mix (TTMM1) and another single 
master mix (TTMM2) to detect 2 TERT mutations: TERT202 and TERT694 was successfully 
achieved. Five forward primers and 5 reverse primers in the TTMM1 master mix to detect 5 
TERT mutants were combined, while also 3 forward primers and 2 reverse primers were also 
combined successfully to detect either a control amplicon (TERT-control) alone or a mutant 
fragment and control amplicon combination. The final PCR cycling conditions and reaction 
set-up for the multiplex of TERT were a common annealing temperature of 55°C for primers, 
30 cycles for PCR cycling, 5% DMSO, two master mixes, TTMM1 (10 primers)  and 
TTMM2 (5 primers) with all containing 25 pmol of all primers with the exception of 50pmol 
of M-TERT694.  
 
The controls for the assay include a mutant negative WT genomic DNA, a negative control 
(containing no template), and a combined mutant positive controls for the specific master 
mix, TTC1 for TTMM1 master mix  and TTC2 for TTMM2 master mix. The final 
TERC/TERT assay will consist of 3 positive controls, TCC, TTC1, and TTC1 which would be 
used as multiple templates to their specific master mix.  TCMM master mix will use positive 
control TCC, while TTMM1 master mix will use a positive control TTC1 and TTMM2 will 
use a positive control TTC2 respectively. The no DNA template will also be used as reagents’ 
negative control in one of the master mixes to ensure that reagents are not contaminated. The 
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3.4 Validation of TERC/TERT assay 
3.4.1 Sensitivity test for the assay assessment  
In order for the assay to be used in a clinical diagnostic setting, it is essential to know the 
limitations of the assay, in relation to the lowest number of mutant alleles that can be 
detected. As the majority of these mutations in AA are clonal, it is important to report this 
sensitivity limit in the case of a negative finding. To determine this lower limit of detection a 
serial dilution of each heterogeneous template (mutant/genomic DNA mix) were performed 
into WT genomic DNA. Templates containing 10%, 5% and 2% mutant alleles were prepared 
as described in section 3.2.1.C and then used as templates in the final TERC and TERT PCR 
reactions as described in sections 3.2.4.A and 3.2.4.B respectively. Each mutant mix was only 
tested with its relevant PCR master mix (TCMM, TTMM1 or TTMM2). The results of this 
dilution series on all of the heterogeneous mixes showed that although the intensity of the 
amplicon decreased with each dilution (as expected), all of the mutants were still able to be 
detected when present at a concentration of 2% mutant alleles (98% WT alleles) (Figures 




Figure 3.22: Sensitivity assessment for the detection of TERC mutations using TCC PCR reaction mix.  
Plasmids containing the TERC SDM PCR products were diluted into WT genomic DNA to produce a dilution 
series of the mutants (20-2% mutant alleles). These were then used as templates with the TCMM reaction mix. 
The picture shows the resulting amplicons that were resolved on a 2% agarose TAE gel stained with ethidium 
bromide and visualized with UV light.  Panel A: analysis of the TERC53C dilution series, B: analysis of the 
TERC178C dilution series. WT = WT genomic DNA used as a template. NC = no template control, MW: 100bp 
molecular weight DNA ladder (NEB).  




Figure 3.23: Sensitivity assessment for the detection of TERT mutations using TTMM1 and TTM2 PCR 
reaction mixes.  
Plasmids containing the TERT SDM PCR products were diluted into WT genomic DNA to produce a dilution 
series of the mutants (20-2% mutant alleles). These were then used as templates with either the TTMM1 or 
TTMM2 reaction mix. The picture shows the resulting amplicons that were resolved on a 2% agarose TAE gel 
stained with ethidium bromide and visualized with UV light.  Panel A: analysis of the TERT202C dilution 
series, using TTMM2, B: analysis of the TERT694C dilution series, using TTMM2. Panel C: analysis of the 
TERT412C dilution series, using TTMM1, WT = WT genomic DNA used as a template. NC = no template 
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3.4.2 Assay reproducibility assessment  
In order to measure the reproducibility of the assay, 3 samples of heterozygous mixes, 
TERC53C and TERT704C (prepared in section 3.2.1.B), and WT genomic DNA (prepared in 
section 3.2.1.A) alone were tested in the assay. Each sample was used as a template in each 
of the 3 assay reactions, TCMM1, TTMM1 and TTMM2 as described in section 3.2.6.B and 
the experiment was repeated 3 times to check precision  and reproducibility of the results.   
 
The correct results were achieved in triplicate with only TERC53 mutant and TERC-control 
amplicons (Figure 3.24.A, Lane 1) produced, using heterogeneous mix TERC53C/WT 
genomic DNA from TCMM1 reaction, while TTMM2 reaction produced only TERT-control 
(Figure 3.24.A, Lane 3) and no amplicon (Figure 3.24.A, Lane 2) produced from TTMM1 
reaction as expected. Using heterogeneous mix TERT704C/WT genomic mix produced only 
correct amplicons of TERC-control (Figure 3.24.B, Lane 4) from TCMM1 reaction, TERT704 
mutant (Figure 3.24.B, Lane 5) from TTMM1 reaction, and TERT-control (Figure 3.24.B, 
Lane 6) from TTMM2 reaction as expected.  
 
Using the WT genomic DNA alone as a template into 3 reactions of the assay produced only 
TERC-control amplicon (Figure 3.24.C, Lane 7) from TCMM, no amplicon (Figure 3.24.C, 
Lane 8) from TTMM1, and only TERT-control amplicon (Figure 3.24.C, Lane 9) from 
TTMM2. After repeating this experiment 3 times, the same results were produced, 
confirming that the assay is reproducible amplifying only correct amplicons from their 
respective reactions of the assay. The repeat of these experiments is shown in Table 3.2 with 
symbols representing amplicons amplified from a correct reaction or no amplification, using 













Figure 3.24: Reproducibility assessment for the detection of TERC/TERT mutations or control amplicons 
using TCMM, TTMM1 and TTM2 PCR reaction mixes.  
Heterogeneous mixes (TERC53/WT genomic DNA and TERT704/WT genomic DNA) and WT genomic DNA 
were used as templates to each reaction mix for the detection of only their targets. Panel A: analysis of 
TERC53/WT genomic DNA mix, using TCMM, TTMM1 and TTMM2. Panel B: analysis of TERT704/WT 
genomic DNA mix using TCMM, TTMM1 and TTMM2. Panel C: analysis of WT genomic DNA using 
TCMM, TTMM1 and TTMM2. The picture shows the resulting amplicons that were resolved on a 2% agarose 
TAE gel stained with ethidium bromide and visualized with UV light. Lane MW: low molecular weight DNA 
ladder (NEB), lane NC: no template control.  
 
 
Table 3.2: Scoring of reproducibility for TERC/TERT assay 
 
π
:  PCR products produced from each reaction mix of the assay  
∑
: First experiment of the assay performed using selected heterogeneous mixes (TERC53C/WT genomic DNA 
and TERT704C/WT genomic DNA) and WT genomic DNA alone as templates.  
Ω
:  First repeat of first experiment  
$
:  Second repeat of first experiment  

:  Shows the amplification of amplicon from a reaction 
ˣ
:  Shows that there was no amplification of amplicon from a reaction 
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3.4.3 Assay accuracy assessment   
To ensure that the TERC/TERT assay could be done accurately and consistently in different 
settings, as would be the case for a diagnostic assay, two different set up of experiments were 
performed. In the first experiment, 4 unknown samples (blind samples) were used, while in 
the other, 5 known negative WT samples (prepared in section 3.2.1.D) as templates were 
used. Both known and unknown samples were tested separately, using the whole TERC/TERT 
assay consisting of 3 PCR reactions (TCMM, TTMM1, and TTMM2). As controls, each 
experiment had 3 positive controls mixes TCC, TTC1, and TTC2 (prepared in section 3.3.7) 
to ensure that the assay was working correctly and samples (known and unknown) can be 
compared with known positive control on every experimental run. The experiments were 
conducted as described in section 3.2.6.C (methods).  
 
Figure 3.25 below shows the TERT/TERC multiplex analysis of the 4 blind samples: the 3 
positive controls and no template controls. The 4 blind samples also showed the correct 
amplification of both control amplicons: TERC-control and TERT-control (Figure 3.25), 
indicating that the DNA was of adequate quality to yield a result. Table 3.3 shows how the 
results of this analysis were scored compared to the subsequently revealed identity of the 
samples. Two unknown samples were found to be TERT positive while other 2 were WT 
samples (Figure 3.25). The known negative samples were WT genomic DNA (Figure 3.26) as 











Figure 3.25:  Electrophoretic analysis of unknown samples amplicons detected using TERC/TERT 
multiplex PCR assay for the assessment of accuracy.  
Four unknown samples were assayed for mutations using the TERT/TERC multiplex assay. Each sample was 
tested on 3 reactions of the assay (as indicted on the figure), with 3 positive controls to check the validity of 




Figure 3.26 Accuracy assessment using healthy individuals DNA as a template in the TERC/TERT 
multiplex PCR assay.  
Five samples of healthy individuals were used as templates on the reaction mixes of the TERC/TERT multiplex 
PCR (as indicated on the figure) to assess the accuracy amplification of the assay to detect TERC and TERT 
mutations.  The experiment included positive control (as indicated on the figure) to ensure that the PCR was 






  MSc Medicine: Haematology 
101 
 
Table 3.3: Scoring of accuracy assessment for TERC/TERT assay 
 
£
: Unknown samples and known negative WT genomic DNA used as templates for the accuracy assessment in       
the TERC/TERT assay.  
€
: PCR product identified from 3 reactions (TCMM, TTMM1, and TTMM2) of TERC/TERT assay.  
 
 
3.5 Cost analysis for the TERC/TERT assay 
The cost and time required to generate a single patient result was calculated using the 
TERC/TERT allele-specific multiplex assay and compared to a result that could be generated 
using DNA sequencing via the standard Sanger sequencing methodology. The costing for the 
TERT/TERC assay was based on a total of 7 PCR reactions for a single patient result: 3 
positive control reactions, a reagent only control and 3 PCR reactions for the patient (or 
patient samples in duplicate). The cost of the sequence analysis was based on 1 PCR reaction 
for the TERC gene and 4 PCR reactions for the TERT exons that contain the relevant 
mutations (PCR products 1000bp<). Sequencing would need to be performed with both the 
forward and reverse primers for each amplicon to confirm the data – thus 10 sequencing 
reactions in total. The prices of the reagents were based on costs as of August 2013 and the 
cost of the technologists’ time is not included in either scenario. The TERC/TERT was more 
cost effective (R409.63) compare to the DNA sequencing (R1148.06) to detect mutations of 
TERC and TERT. In addition to the lower cost, performing the experiments and results 
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Table 3.4: Cost analysis for the TERC/TERT assay and time required to produce results 
 
$
: Subtotal shows the total of each item used during the assay.  
Ω
: Total shows the overall total of all reagents and apparatus used to conduct the assay.  
∑
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Table 3.5:  Cost analysis for DNA sequencing to detect TERC/TERT mutations 
 
π
: Total cost for each item shows each item price used during sequencing. 
β
: Subtotal shows totals for each experiment conducted during DNA sequencing. 
Ω
: Total indicates the overall cost of the DNA sequencing to get results and analysis.  
∑
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3.6 DISCUSSION AND CONCLUSIONS 
 
This study aimed to develop a simple, rapid and cost-effective diagnostic multiplex PCR 
assay to detect all TERT and TERC mutations associated with IST failure in AA. This was to 
be achieved via the development of a two-tube system – one to detect the relevant 7 TERT 
mutations and the other to detect the 4 relevant TERC mutations. These mutations are known 
to cause telomerase complex dysfunction which leads to the production of shortened 
telomeres, thus triggering stem cells to apoptosis and leading to the AA phenotype (Verma et 
al, 2002, Young et al., 2006).  Patients harbouring one of these mutations would indicate that 
the disease is most likely not caused by the common autoimmune pathogenesis and that such 
patients are very likely to fail to respond to the standard IST for this form of AA (Yamaguchi 
et al., 2005, Marrone et al., 2007). Thus knowing the mutational status of an AA patient at 
diagnosis and prior to the initiation of therapy is critical. The IST therapy is very expensive, 
with significant side effects. It is therefore vital that the likelihood that this type of therapy 
would be helpful to the patient is determined.  Additionally, there is evidence that these 
mutations can be inherited and that not all persons carrying these mutations develop AA. 
(Yamaguchi et al., 2005). It is therefore important in AA cases where transplantation is being 
considered that the mutations are not present in the family member donor (Spellman et al., 
2012). 
 
The current method of choice in most laboratories in western countries to detect these 
mutations is DNA sequencing. Mutations of TERC can be detected easily as this gene 
consists of a single exon of only 451bp sequence and four of these mutations: TERC53, 
TERC110, TERC178 and TERC180 are found across the gene. However for TERT it is not 
possible to sequence all seven mutations from one PCR reaction, as the mutations span 5 
exons (the whole gene is 16 exons). At least 4 separate amplifications (500bp-1kb) are 
required to detect these mutations via sequencing. Two mutations of exon 2 (TERT202, and 
TERT412) can be detected simultaneously, as can TERT694 and TERT704 in exon 5 and 
TERT1015 and TERT1090 in exons 14 and 15 respectively. TERT846 in exon 9 requires a 4
th
 
reaction. Independent sequencing of these mutations requires more time to analyse with a 
possibility of detecting clinically irrelevant point mutations (Yamaguchi et al., 2005). In 
addition, sequencing requires that the amplicons are purified to generate good quality data for 
better analysis. This requires additional steps in the laboratory, with increased reaction 
consumables and therefore is rather costly.  
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 Sequencing reactions would also require both forward and reverse primers, used in separate 
reactions, thus increasing the number of reactions and the time factor, as well as cost. We 
therefore decided to develop an alternative assay to detect these mutations which will be 
rapid, simple to interpret and more cost-effective than the current existing DNA sequencing.  
As allele-specific PCR approach has been successfully used previously in the detection of 
point mutations and SNPs, and also in a multi-primer/multiplex setting (Walsh et al., 1992). 
Although an allele-specific PCR approach requires a lot of troubleshooting to find suitable 
PCR cycling and reaction components (Chamberlain et al., 1988, Schoske et al., 2003), we 
decided to use this approach with a benefit of primers binding only in the presence of a 
mutation and detect the gene involved.  
 
Currently there are no commercially available positive controls for these mutations which can 
be used for assay development.  In addition, AA is a rare disease thus few patients are 
available to be used as a source of DNA with these mutations. Therefore we decided to 
generate mutants of TERC and TERT via PCR using SDM primers consisting of a specific 
mutation or deletions that have been reported to be linked to AA development. These mutants 
were successfully generated using SDM PCR as reported in Chapter 2.  We then designed 
allele-specific primers to detect the mutants in an allele-specific multiplex PCR, simulating 
the AA patients sample with one of these mutations by mixing the cloned SDM products with 
WT genomic DNA. These primers provide a discriminatory factor with the mutations located 
at the 3’end and binding to its template only in the presence of that specific mutation 
(Dieffenbach et al., 1993, Hirotsu et al., 2010). We generated these mutants with the aim to 
develop and assay which will be used to detect 4 mutations of TERC and 7 TERT mutations 
using two PCR reaction mixes.  
 
During the development of the TERC multiplex, we found that TERC110 amplification had 
produced non-specific products. But using 3% glycerol we were able to improve the 
specificity and eliminated non-specific products. Markoulatos et al. (2002) suggested that 
using this additive could improve the specificity of amplification as well as increasing the 
PCR efficiency, especially in a multiplex PCR setting. Certainly in this study the specificity 
improved after adding 3% glycerol in a multiplex PCR to amplify TERC mutants. Eventually 
all 4 TERC mutants were able to be amplified from one master mix (TCMM) including the 
experiment positive control amplification amplicon.  
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However when 55°C and above annealing temperature was used M-TC53 and M-TC110 
primer for TERC53 and TERC110 produced non-specific products, but reducing PCR cycling 
to 30 cycles improved the amplification of TERC53. Using 25pmol during the incorporation 
of a control primer (M-TCTRL) into the multi-primer of 4 TERC mutants, some mutants were 
not amplified but reducing the primer concentration to 3.1pmol allowed the amplification of 
all mutants together with a control amplicon (TERC-control). Eventually the detection of all 4 
mutants of TERC was achieved successfully after all the alterations of PCR cycling and 
reaction components.   
 
As we wanted to be able to test for the TERC and TERT mutations at the same time, the 
cycling conditions generated for the TERC amplification had to remain constant for the TERT 
development. Due to this limitation, other parameters had to be changed during the 
development of the TERT multiplex to ensure allele-specificity of the primers and the 
production of sufficient amplicon. This included the addition of 5% DMSO due to 
amplification problems with TERT694, reaction setup on ice (due to amplification issues of 
both TERT694 and TERT704), and different amounts of the various primers. Unfortunately 
despite several attempts, when primers to amplify all 7 mutants of TERT were combined into 
one reaction mix, we found that the PCR efficiency was not sufficient with some primers 
causing significant primer dimerization and preventing the amplification of the amplicons of 
interest.  Primer M-TT694 for TERT694 mutant was found to be responsible for the primer 
dimer formation.  The solution was to divide the detection of TERT mutations across 2 
different PCR reaction mixes: TTMM1 and TTMM2, with TERT412, TERT704, TERT846, 
TERT1015 and TERT1090 detected with TTMM1 and TERT202 and TERT694 with TTMM2.  
 
Hence we finally developed 3 PCR reaction mixes for the entire assay: TCMM for TERC 
mutants, TTMM1 for 5 mutants and TTMM2 for 2 mutants of TERT.  That could all be used 
at the same time. In addition, developing assay controls required that mutants which are 
amplified from one tube of master mix are combined together to be used as multiple 
templates and these controls were TCC1 for TERC and TTC1 and TTC2 for TERT.  Even 
when these mutants were combined, the amplicons of interest were still amplified well, 
showing that they can be used successfully during the assay. Overall the mutants of TERC 
and TERT can be detected using this assay.  
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As indicated in the results section in Chapter 3, when the assay is performed, 2 of 3 reactions 
mixes, TCMM and TTMM2 consist of the reactions positive controls, TERC-control and 
TERT-control respectively. This was done to ensure that there will be an amplicon which will 
be produced in the presence of mutation or not from the patient’s sample that will confirm the 
quality of DNA template used, and these 2 controls were incorporated successfully to these 
reactions mixes. Usually, chemical modifications such as locked nucleic acid based primers, 
zip nucleic based primers or peptide nucleic acid based primers are required to the primers to 
enhance their viability in a multiplex PCR, however in this assay was developed successfully 
without them only normal primers were being used in an allele-specific multiplex PCR. 
Detecting 11 mutations in one simple PCR-gel based assay is noble.    
 
For the assay to be used in the diagnostic environment it requires to be validated. This was 
partially achieved during this study by performing experiments to investigate accuracy, 
reproducibility and sensitivity. The accuracy assessment was assessed by analysis 4 “blinded 
samples” and 5 known WT samples. The results confirmed that the assay was detecting the 
relevant mutations correctly and did not detect false positives. However, this assessment was 
flawed in that a very small number of samples were analysed and no “real” AA patient 
samples were assessed. This was unfortunately due to time constraints and the assay would 
have to be tested with a much larger sample pool to validate this point before it could be used 
in the diagnostic arena. This assay is also reproducible, when the same heterogeneous mixes 
were used in triplicate; the same results were observed − indicating that the assay is 
consistently reproducing the same amplicons. As for the sensitivity, when plasmid constructs 
were diluted into genomic DNA making it to 98% WT and 2% mutation, the mutations were 
still detected, confirming that the assay is sensitive and able to detect even below 20% 
clinically relevant lower limit of detection when using sequencing.  This could help to detect 
the mutations even if the number of alleles is very low from the DNA sample of a patient, 
showing that this assay could be more clinically relevant to detect mutations, probably better 
than DNA sequencing that has 20% sensitivity. 
 
In conclusion, a diagnostic multiplex PCR assay to detect all TERC and TERT mutations 
associated with AA was developed successfully. This assay can be applicable to screen these 
clinically relevant mutations with the advantage of being simple, easy to prepare and able to 
produce a result within the same day as sample receipt if necessary. 
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 Its cost is significantly cheaper compared to the currently existing methods to detect 
mutations, considering that in this assay 11 mutations are detected at the same time, with less 
time required to conduct the experiment. This assay can be applicable not only in AA 
patient’s diagnoses but also can be used in other diseases related to telomerase complex 
dysfunction, such DKC, IPF and others.   
 
Future work would be to certify TERC/TERT assay by validating the assay to check accuracy 
using positive control AA patients or DKC patients, especially those known to have certain 
TERC/TERT mutations to ensure that the assay does detect those mutations. In addition, since 
only 5 healthy individuals were used during the assay development and accuracy test, it 
would be recommended to test a larger number of healthy individuals from various 
populations groups in South Africa.   This will ensure that mutations investigated during the 
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